| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Aethlon Medical, Inc.$0.66
+0.1 (+17.1%)
F 10Pipeline Score MedTech · Clinical
Market Cap
3.47 M
EPS
-45.83
P/E Ratio
-0.05 $
Value Trade
573.39 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.91 M
Operating CF
-7.00 M
Total Assets
6.33 M
Total Liabilities
1.45 M
Equity
4.89 M
D/E Ratio
12,345
2.8 %
Week
-3.93 %
1 Month
7.84 %
3 Month
-38.55 %
6 Month
-99.84 %
5 Year
-100 %
All Time
Cash Data
Cash Position
5.03 M
Monthly Burn
583.00 K
Runway
7 mo
Burn Trend
SEC Filing
Jun 10, 2026
Overview
Volume
1.28 M
52 Week Range
1.36 - 29.88
% held by Insiders
2.67 %
% held by Institutions
5.82 %
Enterprise Value
-3.07 M
Total Shares
1.57 M
Short %
14.84 %
Float Shares
1.54 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-12-02 | Hemopurifier® (investigational extracorporeal device) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-12-02 | Hemopurifier® (investigational extracorporeal device) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-12-02 | Hemopurifier® (investigational extracorporeal device) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 9%
Micro Cap (rank 832 of 913)
Percentile RankAethlon Medical, Inc. has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Hemopurifier Breakthrough | cancer not responding to anti-PD-1 therapy | — | 2025-10-07 | changes in extracellular vesicles; changes in microRNAs; changes in lymphocyte counts Read More | Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial Read More | |
Hemopurifier Breakthrough | cancer not responding to anti-PD-1 therapy | — | 2025-10-07 | changes in extracellular vesicles; changes in microRNAs; changes in lymphocyte counts Read More | Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial Read More | |
Hemopurifier Breakthrough | cancer not responding to anti-PD-1 therapy | — | 2025-10-07 | changes in extracellular vesicles; changes in microRNAs; changes in lymphocyte counts Read More | Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AEMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AEMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AEMD▼ -5.5%on this news
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
Aethlon Medical reported that the second cohort of its Australian oncology trial showed biological changes consistent with the first cohort after treatment with the Hemopurifier. These findings support the ongoing clinical program and the enrollment of a third cohort. The company plans an independent statistical analysis to evaluate the potential dose-response relationship of the treatment. However, the results are preliminary and do not yet demonstrate clinical efficacy.
Read more →AEMD▲ +11.3%on this news
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Aethlon Medical, Inc. has announced the pricing of a follow-on offering of 5,633,009 shares at $0.7101 per share, expected to close on July 7, 2026. The offering aims to raise approximately $4.0 million to fund general corporate purposes, including R&D and clinical trials. The company is also focused on developing its Hemopurifier device for cancer and viral infections.
Read more →AEMDAethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®
Aethlon Medical announced a peer-reviewed study revealing that Long COVID patients have elevated levels of mannosylated extracellular vesicles. These vesicles can be captured by the Hemopurifier, suggesting its potential as a treatment for Long COVID. The findings support further research into the Hemopurifier's applications across various diseases.
Read more →AEMDAethlon Medical Announces Fiscal Year End
Aethlon Medical reported its financial results for the fiscal year ending March 31, 2026, along with updates on its Australian oncology study. The company has advanced to Cohort 3 in its clinical trial, where the first participant has been treated successfully. Significant progress has also been made in strengthening the company's intellectual property portfolio, particularly in areas related to long COVID and other coronavirus conditions. Despite achieving clinical milestones, Aethlon continues to experience financial losses and a need for careful management of its operating expenses.
Read more →AEMDAethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Aethlon Medical reported its fiscal year-end results for March 31, 2026, highlighting advancements in its Australian oncology study, which has now entered its third dosing cohort. The company also expanded its Hemopurifier intellectual property portfolio and achieved a significant reduction in operating expenses. Despite these advancements, Aethlon continues to face substantial net losses and limited cash reserves.
Read more →AEMD▼ -8.3%on this news· ran to -21% by day 3
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
Aethlon Medical, Inc. will announce its fiscal year-end financial results on June 10, 2026, followed by a conference call to discuss the results and recent developments. The Hemopurifier, a key product in their pipeline, has shown promise in clinical studies for treating cancer and life-threatening viral infections. Interested parties can register for the call or access a replay afterward.
Read more →AEMDAethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
Aethlon Medical is monitoring the Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda, reaffirming its preparedness to engage with healthcare authorities regarding its Hemopurifier technology. The device has shown potential in past cases, although it remains investigational for Ebola treatment. The company emphasizes the need for broad-spectrum therapies in the face of limited approved treatments.
Read more →AEMD▼ -6.1%on this news
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
Aethlon Medical, Inc. has received a positive recommendation from the Data Safety Monitoring Board (DSMB) to advance to the final cohort of its clinical trial for the Hemopurifier device. The DSMB noted no safety concerns during their review of the second cohort, allowing the trial to proceed with further evaluations of safety and dosing. Enrollment for the final cohort is now open, with participants receiving three treatments over a week.
Read more →AEMDAethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
Aethlon Medical has engaged Maxim Group LLC as its exclusive financial advisor to explore strategic opportunities, including potential partnerships and acquisitions. The company is also progressing with its oncology trial in Australia, having completed the second cohort. However, there is no set timeline for the evaluation process, and no guarantees exist regarding the outcome of these discussions.
Read more →AEMDAethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
Aethlon Medical, Inc. will present at the Emerging Growth Conference on February 25, 2026. The event will feature a live interactive session with the CEO and CFO, allowing attendees to engage directly. The Hemopurifier, an investigational device for treating cancer and infectious diseases, holds a Breakthrough Device Designation from the FDA.
Read more →AEMDAethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
Aethlon Medical reported its fiscal Q3 2026 financial results, highlighting ongoing clinical trials and cost efficiencies. The company is advancing its Hemopurifier technology, showing promise in cancer treatment and Long COVID research. Despite an increase in operating loss, Aethlon's commitment to clinical programs remains strong, with a focus on optimizing costs.
Read more →AEMDAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
Aethlon Medical, Inc. will announce its fiscal third quarter financial results on February 12, 2026, at 4:15 p.m. ET. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the results and recent developments. The Hemopurifier device, aimed at treating cancer and viral infections, has received FDA Breakthrough Device designation.
Read more →AEMD▲ +6.5%on this news
Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
Aethlon Medical, Inc. has announced a private placement agreement with an institutional investor, aiming to raise approximately $3.3 million. The deal includes the sale of shares and warrants priced at $4.03 each. The offering is expected to close by December 8, 2025, pending customary conditions. The company plans to use the funds to further develop its Hemopurifier technology.
Read more →AEMD▼ -23.5%on this newsshared move
Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs
Aethlon Medical has published preclinical data indicating that its Hemopurifier can bind to extracellular vesicles in Long COVID patient samples, potentially decreasing inflammatory microRNAs. This study, conducted in collaboration with UCSF, suggests that the Hemopurifier may serve as a therapeutic option for Long COVID, which currently lacks effective treatments.
Read more →AEMD▲ +12.9%on this news
Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
Aethlon Medical, Inc. reported its fiscal Q2 2025 financial results, highlighting significant progress in clinical trials and a 48% reduction in operating expenses. The company is advancing its Hemopurifier device in oncology trials, with recruitment for a second cohort underway. Despite positive developments, challenges remain, including the limited effectiveness of current therapies for patients.
Read more →AEMDAethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
Aethlon Medical, Inc. will release its fiscal second quarter financial results on November 12, 2025, at 4:15 p.m. ET. Following this, a conference call will be held at 4:30 p.m. ET to discuss the results and recent corporate developments. The Hemopurifier, an investigational device, aims to treat advanced cancer and life-threatening viral infections.
Read more →AEMD▼ -5.8%on this news
Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
Aethlon Medical has reported preliminary findings from its oncology clinical trial in Australia, focusing on the Hemopurifier device. Initial results from three patients indicate positive changes in extracellular vesicles, microRNAs, and lymphocyte counts after treatment. However, the company cautions that these observations do not imply clinical efficacy, as further data is needed from subsequent cohorts.
Read more →AEMDAethlon Medical Announces Pricing of $4.5 Million Public Offering
Aethlon Medical has announced a public offering of 5 million shares at $0.90 each, aiming to raise approximately $4.5 million. The proceeds will be used for general corporate purposes, including clinical trials and research. The offering is expected to close around September 5, 2025, pending customary conditions.
Read more →AEMD▼ -17.7%on this news· ran to -59% by day 3shared move
Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)
Aethlon Medical announced the issuance of two patents for its Hemopurifier device, aimed at treating Long COVID and COVID-19-associated coagulopathy. The U.S. Patent No. 12,409,260 will protect the use of the device for patients with Long COVID symptoms, while the Unitary European Patent 4136453 covers treatment for CAC. These patents enhance Aethlon's intellectual property in critical medical areas.
Read more →AEMD▲ +97.3%on this news
Corporate Presentation The Hemopurifier FORWARD LOOKING STATEMENTS 2 This investor presentation contains forward - looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 as co
Aethlon Medical presented an overview of its Hemopurifier technology, designed for blood purification in oncology and infectious diseases. The device has received FDA Breakthrough Device designations and shows potential in clearing enveloped viruses and extracellular vesicles based on early clinical trials. Multiple clinical trials are underway, particularly in Australia, which may yield significant data soon. However, the company faces several risks related to trial enrollment, regulatory approvals, and market acceptance.
Read more →AEMDAethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update
Aethlon Medical reported financial results for Q1 2025, highlighting progress in its Australian oncology trial where the first treatment cohort was successfully completed. The company has reduced operating expenses by 32% and is advancing its Hemopurifier device, which aims to improve responses in patients unresponsive to PD-1 inhibitors. However, the initiation of a trial in India has been postponed to 2026, focusing resources on the Australian study.
Read more →AEMDAethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025
Aethlon Medical, Inc. has announced plans to release its fiscal first quarter financial results for the period ending June 30, 2025, on August 13, 2025. A conference call will be held on the same day to discuss these results and recent corporate developments. The company continues to advance its investigational device, the Hemopurifier, which is aimed at treating serious conditions related to cancer and infectious diseases, having previously received Breakthrough Device Designation from the FDA.
Read more →AEMDAethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort
Aethlon Medical, Inc. announced that the Data Safety Monitoring Board has completed its safety review of the ongoing clinical trial AEMD-2022-06 and recommended advancing to the next patient cohort. The trial assesses the safety and feasibility of the Hemopurifier in patients with solid tumors. No serious adverse events have been reported, indicating a favorable safety profile.
Read more →AEMD▼ -35.6%on this news
Earnings Script Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended
Aethlon Medical reported its financial results for the fourth quarter of fiscal 2025, highlighting the treatment of the first three patients in their Hemopurifier cancer trial and receiving Indian regulatory approval for a similar study. The company has significantly reduced its operating expenses by approximately 26%, which positions it favorably for future clinical and regulatory objectives. The Hemopurifier's preclinical success could lead to broader applications in treating diseases associated with extracellular vesicles. Aethlon is also collaborating with UCSF on Long COVID research, demonstrating their focus on innovative therapeutic developments.
Read more →AEMD▲ +23.6%on this newsshared move
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
Aethlon Medical reported its financial results for Q4 fiscal 2025 and provided an update on its clinical trials, including the successful treatment of three patients using the Hemopurifier in a cancer trial. The company received regulatory approval in India to initiate a similar study and has reported a significant reduction in operating expenses. Preclinical data suggest the Hemopurifier effectively removes extracellular vesicles implicated in cancer. These developments reflect the company's ongoing efforts to expand its therapeutic applications, including investigations into Long COVID.
Read more →AEMD▼ -9.2%on this news· ran to -20% by day 1
Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025
Aethlon Medical, Inc. announced that it will release its fiscal fourth quarter financial results on June 26, 2025, and will host a conference call at 4:30 p.m. ET on the same day. The call will include a review of financial results and corporate developments, followed by a Q&A session. Aethlon's Hemopurifier device, designed to combat cancer and severe viral infections, has been recognized by the FDA as a Breakthrough Device, highlighting its potential impact in the field.
Read more →AEMDAethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial
Aethlon Medical has enrolled and treated a second patient in its Hemopurifier clinical trial in Australia, aimed at patients with solid tumors who are unresponsive to anti-PD-1 therapies. Both patients treated so far have reported no immediate complications, which is a positive sign for the device's safety profile. A Data Safety Monitoring Board will review the safety data once a third participant is treated. The ongoing trial will assess the effectiveness of the Hemopurifier in potentially enhancing responses to existing therapies.
Read more →AEMD▼ -12.9%on this news· ran to -25% by day 3
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Aethlon Medical announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and other post-acute infection syndromes. They will present data on the Hemopurifier's ability to bind extracellular vesicles in long COVID samples, a significant advancement given the lack of effective treatments. This research was conducted in collaboration with the University of California, San Francisco Medical Center. The presentation is scheduled for August 12, 2025, and will contribute to the understanding of long COVID's pathogenesis.
Read more →AEMDAethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma
Aethlon Medical has published preclinical data demonstrating the effectiveness of its Hemopurifier in removing platelet-derived extracellular vesicles (PD-EVs) from plasma. The study indicated a significant 98.5% removal rate and reinforces the potential use of the device in ongoing oncology clinical trials in Australia. The Hemopurifier may serve as a therapeutic strategy for multiple indications, including cancer and life-threatening infectious diseases. The company plans to submit these findings for peer review and explore further applications in treating various diseases related to PD-EVs.
Read more →AEMD▼ -5.5%on this news
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal
Aethlon Medical has announced the publication of preclinical data in the Transplant Immunology journal, showcasing the potential of its Hemopurifier® in improving kidney transplantation outcomes. The study indicates that the device can efficiently remove harmful extracellular vesicles and microRNAs from discarded kidneys, aiming to mitigate complications such as delayed organ function and rejection. While the results are promising, Aethlon highlights the need for further evaluation and clinical trials to substantiate these findings and integrate the Hemopurifier® into existing renal perfusion technologies.
Read more →AEMD▼ -5.5%on this news
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
Aethlon Medical, Inc. (Nasdaq: AEMD) has announced its participation in the Emerging Growth Conference scheduled for February 19, 2025. During the event, CEO James Frakes will deliver a presentation and engage with investors through a question-and-answer session. This conference aims to facilitate communication between public companies and the investment community. Aethlon Medical is recognized for its development of the Hemopurifier, a device designed to combat cancer and life-threatening infections.
Read more →AEMDAethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
Aethlon Medical announced its financial results for the fiscal third quarter ending December 31, 2024, highlighting significant progress in its oncology trials, particularly the treatment of the first patient using its Hemopurifier. The company has made strategic amendments to its trial protocols which aim to enhance patient enrollment and operational efficiency. Despite a reduction in operational costs by around 50%, the withdrawal of two patients from the trial due to outcomes associated with anti-PD-1 therapy raised concerns. Regulatory hurdles in India may also pose challenges for Aethlon's clinical trial expansion.
Read more →AEMD▲ +8.6%on this news
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
Aethlon Medical, Inc. (AEMD) has announced a scheduled release of its fiscal third quarter financial results for the period ending December 31, 2024, on February 12, 2025. The company's management will host a conference call to discuss the results and recent corporate developments. The Hemopurifier device, aimed at treating cancer and viral infections, holds FDA Breakthrough Device designation, indicating its importance in medical advancements. However, the announcement also includes forward-looking statements, emphasizing the risks and uncertainties facing the company.
Read more →AEMD▲ +19%on this news
Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial
Aethlon Medical has successfully treated its first patient with the Hemopurifier in a clinical trial conducted in Australia. This trial focuses on patients with solid tumors who have shown stable or progressive disease during anti-PD-1 therapy. The treatment aims to assess the feasibility and safety of the Hemopurifier, which is designed to remove tumor-derived extracellular vesicles from the bloodstream. This milestone could potentially lead to improved therapeutic responses for certain cancer patients.
Read more →AEMD▲ +33.8%on this news
Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu
Aethlon Medical has provided an update on its Hemopurifier device regarding its ability to capture H5N1 Bird Flu. Amid reports of human infections and a state of emergency in California, Aethlon highlighted promising results from in vitro studies showing the device's effectiveness in removing up to 99% of H5N1. While the Hemopurifier has been used in multiple patient treatments for other severe diseases, it has not yet been used specifically for H5N1 cases. Aethlon plans to monitor the situation closely and may interact with healthcare authorities if the need arises.
Read more →AEMDAethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
Aethlon Medical, Inc. has reported financial results for its fiscal second quarter ended September 30, 2024, highlighting significant progress in its oncology trials. The company has enrolled its first two patients in Australia for the Hemopurifier® in patients with solid tumors who did not respond to anti-PD-1 antibodies. Additionally, it has received ethics committee approval for a trial site in India. Strategic cost-cutting measures have been implemented to enhance operational efficiency. The company reported a reduced net loss, indicating some financial improvement.
Read more →AEMD▲ +6%on this newsshared move
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
Aethlon Medical has announced the enrollment of the first patient in its Hemopurifier clinical trial for cancer treatment in Australia. This trial focuses on safety, feasibility, and dose-finding for patients with solid tumors who are not responding to existing anti-PD-1 therapies such as Keytruda and Opdivo. The trial's aim is to assess whether the Hemopurifier can improve treatment outcomes by removing tumor-derived extracellular vesicles from the blood. The study begins with a two-month run-in period followed by monitoring for potential improvements in tumor response.
Read more →AEMDAethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
Aethlon Medical, Inc. announced it will release its fiscal second quarter financial results on November 13, 2024, followed by a conference call for stakeholders. The Hemopurifier, a key product in their pipeline, is FDA-designated as a Breakthrough Device for certain cancer cases and severe infections. Interested participants can access the conference call via registration or dial-in methods. Forward-looking statements highlight the potential risks and uncertainties surrounding the company's future performance.
Read more →AEMD▼ -7%on this news
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
Aethlon Medical, Inc. (AEMD) will participate in the 2024 Maxim Healthcare Virtual Summit on October 15, 2024. CEO and CFO James Frakes will engage in a fireside chat during the event, which is hosted by Anthony Vendetti. The company focuses on innovative treatment solutions, particularly the Hemopurifier, designed to combat cancer and severe viral infections. The Hemopurifier has received FDA Breakthrough Device designation, highlighting its potential in addressing serious health conditions.
Read more →AEMD▲ +8.8%on this news· ran to +21% by day 3
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
Aethlon Medical received full ethics approval from the Medanta Institutional Ethics Committee for its clinical trial of the Hemopurifier in cancer patients who are not responding to anti-PD-1 antibodies. The trial, focused on safety, feasibility, and dose-finding, will be conducted in India and is set to begin patient recruitment in the fourth quarter of 2024. This study aims to evaluate the Hemopurifier's effectiveness in removing cancer-associated extracellular vesicles, which may enhance treatment responses in solid tumors. Prior approvals have been secured in Australia, showcasing progress in Aethlon's international clinical strategy.
Read more →AEMDAethlon Medical to Present at Virtual Investor Conferences in September
Aethlon Medical, Inc. announced its participation in upcoming virtual investor conferences in September where management will present the company's overview and discuss its innovative Hemopurifier technology. The Life Sciences Investor Forum is scheduled for September 19-20, while the Virtual Emerging Growth Conference is set for September 25. These events allow investors to engage in Q&A sessions with the management team, fostering transparency and investor relations. Aethlon's Hemopurifier device is designed to treat cancer and severe infections, holding FDA Breakthrough Device designation.
Read more →AEMDAethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
Aethlon Medical has announced the activation of the Royal Adelaide Hospital for patient screening and enrollment in a clinical trial for its Hemopurifier device. This trial will focus on patients with solid tumors that have not responded to anti-PD-1 therapies like Keytruda and Opdivo. Along with this primary site, Aethlon plans to activate additional locations and is seeking further regulatory approvals. The trial aims to explore the Hemopurifier's potential to improve treatment responses by targeting extracellular vesicles linked to cancer progression.
Read more →AEMD▼ -7.4%on this news· ran to -26% by day 3
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
Aethlon Medical announced the preprint publication of a study revealing that its Hemopurifier® can effectively remove extracellular vesicles and microRNAs from renal perfusates of discarded donor kidneys. This proof-of-concept study is vital as it suggests potential applications for the Hemopurifier in improving kidney transplantation outcomes. The company aims to conduct further studies, including preclinical trials, to assess the device's efficacy in a clinical setup. The findings represent a promising step toward addressing organ shortage issues and enhancing transplant recipient success rates.
Read more →AEMD▲ +15.9%on this news· ran to +39% by day 3
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update
Aethlon Medical, Inc. reported financial results for its fiscal first quarter ending June 30, 2024, showing a net loss of approximately $2.6 million, a decrease from the previous year's loss. The company received two ethics committee approvals for clinical trials involving its Hemopurifier® system aimed at treating patients with solid tumors not responding to anti-PD-1 therapies. They anticipate initiating patient enrollment in October 2024. Additionally, a significant reduction in operating expenses by 24% was achieved compared to the same quarter in the prior year.
Read more →AEMDAethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial
Aethlon Medical has received its second ethics committee approval for a clinical trial of the Hemopurifier in patients with solid tumors who are not responding to anti-PD-1 therapies. This approval from the Bellberry Human Research Ethics Committee pertains to a study at Pindara Private Hospital in Australia, aimed at evaluating the device's safety and feasibility. The study will investigate the Hemopurifier's ability to remove extracellular vesicles that may hinder treatment efficacy. Patient enrollment is contingent upon further approvals from hospital governance offices.
Read more →AEMD▲ +11.5%on this news
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024
Aethlon Medical, Inc. announced it will release its fiscal first quarter financial results on August 14, 2024. A conference call will follow to discuss these results and other corporate developments. The company focuses on the Hemopurifier, a device aimed at treating cancer and serious infections, which has received FDA Breakthrough Device designation. However, the company faces several risks, including challenges in capital raising and trial management.
Read more →AEMDAethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update
Aethlon Medical, Inc. has reported its financial results for the fiscal year ending March 31, 2024, alongside a corporate update. The company is actively advancing its Hemopurifier therapeutic system, which aims to treat cancer and other severe infections. A significant milestone includes the recent approval for a clinical trial in Australia targeting cancer patients undergoing anti-PD-1 therapy. However, Aethlon also reported a net loss increase to $12.2 million, emphasizing challenges alongside their advancements.
Read more →AEMDAethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
Aethlon Medical, Inc. (AEMD) announced it will release its fiscal year-end financial results for 2024 on June 27, 2024, followed by a management conference call. The call, scheduled for the same day, will review financial results and recent developments. Aethlon's Hemopurifier device is notable for its FDA Breakthrough Device designation, aimed at treating advanced cancer and life-threatening viruses.
Read more →AEMD▲ +5.4%on this newsshared move
Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial
Aethlon Medical has been granted full ethics approval for a clinical trial of its Hemopurifier device intended for cancer patients with solid tumors who have not responded to anti-PD-1 therapies. The trial, set to take place at the Royal Adelaide Hospital in Australia, aims to assess the safety and feasibility of the Hemopurifier in enhancing treatment outcomes. The approval from the Human Research Ethics Committee is valid for three years, reflecting compliance with ethical research standards in Australia. Aethlon plans to further submit to additional ethics boards as part of the trial's next steps.
Read more →AEMD▲ +5.3%on this news· ran to +26% by day 3
Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
Aethlon Medical is advancing towards its Phase 1 clinical trials for the Hemopurifier, targeting patients with solid tumors undergoing anti-PD-1 monotherapy. Key updates include progress in obtaining Ethics Committee approvals in Australia and India, as well as promising preliminary data on the device's ability to remove harmful exosomes from cancer patient plasma. The company aims to finalize Clinical Trial Agreements post-approval to begin patient recruitment. The Hemopurifier is recognized by the FDA as a Breakthrough Device intended for treating advanced or metastatic cancer.
Read more →AEMD▼ -52.9%on this news
Aethlon Medical Announces Pricing of $4.7 Million Public Offering
Aethlon Medical, Inc. announced the pricing of a public offering, aiming to raise a total of $4.7 million through the sale of shares and warrants. The proceeds are designated for general corporate purposes, including clinical trials and R&D related to their immunotherapeutic device, the Hemopurifier, which is focused on treating cancer and viral infections. The offering is set to close on May 17, 2024, pending customary closing conditions. Maxim Group LLC is acting as the exclusive placement agent for this offering.
Read more →AEMDAethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
Aethlon Medical announced positive results from an in vitro binding study of its Hemopurifier aimed at removing extracellular vesicles from the plasma of cancer patients. This study provides pre-clinical evidence that will support the design of a planned phase 1 trial in patients with solid tumors receiving anti-PD-1 monotherapy. While the data indicates the potential efficacy of the Hemopurifier, challenges remain, including the need for further validation regarding specific extracellular vesicle subsets and obtaining necessary regulatory approvals.
Read more →AEMDNasdaq: AEMD www.AethlonMedical.com Corporate Presentation April 2024 FORWARD LOOKING STATEMENTS This investor presentation contains forward - looking statements, as that term is defined in the Private Securities Litigat
Aethlon Medical has presented details about its Hemopurifier device, which received FDA designation as a 'Breakthrough Device' for its potential in treating cancer and severe viral infections. The company aims to demonstrate the effectiveness of the Hemopurifier in ongoing and planned clinical trials across various patient populations. However, Aethlon faces challenges in patient enrollment, regulatory approvals, and securing funding for its operations and trials. The company is actively pursuing international clinical research opportunities to broaden its therapeutic applications.
Read more →AEMDAethlon Medical Enters Into Materials Transfer Agreement for Santersus AG
Aethlon Medical, Inc. has entered into a Materials Transfer Agreement with Santersus AG to explore the potential synergies between their respective medical devices. The agreement allows Aethlon to perform pre-clinical studies on Santersus' NucleoCapture and HemoNucleoCapture devices, which target Neutrophil Extracellular Traps (NETs) associated with various diseases. This collaboration aims to investigate the combined efficacy of these devices with Aethlon's Hemopurifier in treating cancer patients and enhancing organ transplant procedures. The partnership represents a significant step in advancing both companies' technologies and research capabilities.
Read more →AEMDAethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
Aethlon Medical reported its fiscal third quarter financial results for 2023, highlighting ongoing developments for its Hemopurifier, a device targeting cancer and viral infections. The company received clearance from Indian authorities to begin a phase 1 trial for patients with solid tumors on anti-PD-1 therapy. While the Hemopurifier shows potential, internal data is inconclusive, prompting the company to collaborate with third-party labs for validation. Financially, Aethlon experienced a rise in net loss, attributed to increased operating expenses, yet remains committed to its oncology program and cost reduction efforts.
Read more →AEMDAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
Aethlon Medical, Inc. will announce its fiscal third quarter results on February 14, 2024, at 4:15 p.m. ET, followed by a conference call at 4:30 p.m. ET. The company, known for its Hemopurifier device targeting cancer and infectious diseases, holds an FDA Breakthrough Device designation. The call will include a review of financial results and recent corporate developments, along with a Q&A session for interested stakeholders.
Read more →AEMDAethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
Aethlon Medical reported its fiscal second-quarter financial results and provided a corporate update, highlighting advancements in the development of the Hemopurifier, a therapeutic device for treating cancer and infectious diseases. The company received clearance from India's drug authority for a phase 1 trial in solid tumor patients. Leadership transitions were also announced, with James B. Frakes appointed as Interim CEO. However, challenges related to supply chain disruptions were acknowledged, particularly concerning a vital component of the Hemopurifier.
Read more →AEMDAethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer
Aethlon Medical, Inc. has appointed James B. Frakes as Interim CEO and Guy Cipriani as COO, effective November 7, 2023. Frakes, who has over 30 years of experience in public companies, expressed eagerness to lead the company in its innovative efforts against cancer and viral infections. The Hemopurifier technology, for which Aethlon is known, has achieved FDA Breakthrough Device designation and is set to enter phase 1 clinical trials in India. The transition comes with gratitude for past CEO Charles J. Fisher's service.
Read more →AEMDAethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023
Aethlon Medical, Inc. announced that it will release its second-quarter financial results for the period ending September 30, 2023, on November 14, 2023, at 4:15 p.m. ET. Following the results, management will host a conference call at 4:30 p.m. ET to discuss the findings and recent corporate developments, followed by a Q&A session. The Hemopurifier device, which targets cancer and life-threatening viral infections, has received FDA Breakthrough Device designation, indicating its significance in treatment options.
Read more →AEMDAethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology
Aethlon Medical has received clearance from the Drug Controller General of India to conduct a phase 1 trial of its Hemopurifier in patients with solid tumors. This study will evaluate the safety and feasibility of the device alongside anti-PD-1 therapies such as Keytruda and Opdivo. The trial aims to examine different dosing intervals and their effects on the immune response. Aethlon also plans a similar trial in Australia, which will contribute to future efficacy studies.
Read more →AEMD▼ -10.9%on this news
Aethlon Announces Reverse Stock Split
Aethlon Medical, Inc. (Nasdaq: AEMD) has announced a 1-for-10 reverse stock split, effective October 4, 2023. This move aims to enable the company to meet Nasdaq listing requirements, thus facilitating access to capital markets to support its clinical programs, particularly involving the Hemopurifier. The Board of Directors had previously approved a reverse stock split ratio in the range of 1-for-8 to 1-for-12. No fractional shares will be issued; affected shareholders will receive whole shares only.
Read more →AEMDAethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aethlon Medical, Inc. will present an overview at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. The presentation will include insights from CMO Steven LaRosa and CFO James Frakes. The Hemopurifier, a key product from Aethlon, targets cancer and life-threatening viral infections and has received FDA Breakthrough Device designation. The company will also facilitate in-person meetings with institutional investors during the event.
Read more →AEMDAethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update
Aethlon Medical, Inc. reported its financial results for the fiscal first quarter ending June 30, 2023, revealing a net loss of approximately $3.3 million. The company has made progress with its Hemopurifier, which has potential applications in oncology and organ transplants, and is actively pursuing clinical studies in both areas. Aethlon also continues its COVID-19 trial in India, expanding patient enrollment with the addition of a second clinical site. Overall, while the company is advancing its product development, financial losses have increased compared to the previous year.
Read more →AEMDAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 10, 2023
Aethlon Medical, Inc. (Nasdaq: AEMD) has announced it will release its first-quarter financial results on August 10, 2023, and host a conference call for interested parties. The call will review the financial outcomes and recent corporate developments, with an opportunity for questions. The company is focused on developing the Hemopurifier, a device aimed at treating cancer and life-threatening infections, which has received FDA Breakthrough Device designations. However, it also acknowledged risks that may affect the future success of its innovations.
Read more →AEMDAethlon Medical Signs Collaboration Agreement with 34 Lives to Evaluate the Ability of the Hemopurifier® to Expand the Utility of Unused, Donated Kidneys for Transplant
Aethlon Medical has entered a collaboration with 34 Lives to explore the potential of its Hemopurifier technology to enhance the viability of donated kidneys for transplantation. The initiative aims to mitigate complications post-transplant by removing harmful viruses and exosomes from donor organs. According to industry reports, significant numbers of kidneys go unused each year, highlighting the urgency of innovating in organ preservation. This partnership may address the challenge of a long patient waitlist for transplants, particularly for kidneys.
Read more →AEMDAethlon Medical Appoints Medical Device and Biomedical Executive, Nicolas Gikakis, to its Board of Directors
Aethlon Medical has appointed Nicolas Gikakis to its Board of Directors, effective July 3, 2023. Gikakis, a seasoned executive with over 20 years in the medical device and biomedical industries, will also serve on the Nominating and Corporate Governance Committee. His appointment expands the board to six members and aims to enhance the pursuit of developing Aethlon's Hemopurifier, a therapeutic device for treating cancer and life-threatening infections. The company hopes Gikakis' experience will contribute positively during this pivotal time.
Read more →AEMDAethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
Aethlon Medical, Inc. (AEMD) announced its financial results for the fiscal year ending March 31, 2023, reporting a net loss of $12 million and rising operating expenses. The company is advancing its Hemopurifier technology, with ongoing clinical trials targeting COVID-19 in India and an upcoming oncology trial in Australia. Additionally, Aethlon is investigating the use of its Hemopurifier in organ transplantation to enhance organ preservation. The company holds approximately $14.5 million in cash as of March 31, 2023.
Read more →AEMDAethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023
Aethlon Medical, Inc. announced that it will release its financial results for the fourth quarter ending March 31, 2023, on June 28, 2023. Management will hold a conference call that day to discuss the results and recent corporate developments. The company’s Hemopurifier device is designed to treat cancer and infectious diseases and has received FDA Breakthrough Device designation. However, the announcement includes warnings regarding potential risks and uncertainties related to its development and funding.
Read more →AEMDAethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation
Aethlon Medical has announced it is investigating the use of its Hemopurifier device in the organ transplant market, aiming to confirm its ability to remove harmful viruses and exosomes from harvested organs. This research could lead to reduced complications such as viral infections and organ rejection post-transplant. Aethlon's device has been previously recognized as a Breakthrough Device by the FDA, indicating its significant therapeutic potential. The company acknowledges that this new initiative may help to increase the viability of organs for transplantation, although success is not guaranteed.
Read more →AEMDAethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest
Aethlon Medical, Inc. will present a company overview at the Healthcare Virtual Conference on June 21, 2023. CEO Charles J. Fisher, Jr. and CFO James Frakes will lead the presentation. Additionally, the company's management will engage in one-on-one meetings with investors during the event. Aethlon is focused on developing the Hemopurifier, a device designed to tackle cancer and serious viral infections, which holds FDA Breakthrough Device designation.
Read more →AEMDAethlon Medical to Present at the 13th Annual LD Micro Invitational
Aethlon Medical, Inc. announced that its key executives will present an overview at the 13th Annual LD Micro Invitational on June 7, 2023. The conference, scheduled for June 6-8 in Los Angeles, is an opportunity for management to engage with investors through one-on-one meetings. The focus will be on Aethlon's Hemopurifier, a device aimed at tackling cancer and life-threatening infections, which holds FDA Breakthrough Device designations.
Read more →AEMDAethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifier® to Treat Severe COVID-19 in India
Aethlon Medical has announced the receipt of Ethics Review Board approval for a second site in its ongoing clinical trial of the Hemopurifier in India. The Maulana Azad Medical College will join existing trials to potentially improve patient enrollment for severe COVID-19 treatment. The trial is designed to treat up to 15 patients across three centers, with one patient already treated at the initial site. These developments suggest an expanding opportunity for the Hemopurifier in addressing life-threatening infections.
Read more →AEMDAethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
Aethlon Medical reported its third quarter financial results, revealing a net loss increase to approximately $2.85 million. The company is advancing the clinical development of its Hemopurifier, having engaged NAMSA for an upcoming oncology study. Furthermore, Dr. Lee Arnold has been appointed as Chief Scientific Officer, expected to bolster the company’s research initiatives. Despite these advancements, challenges remain, particularly regarding government contract milestones.
Read more →AEMDAethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023
Aethlon Medical, Inc. (NASDAQ: AEMD) announced it will release its third quarter financial results for the period ending December 31, 2022, on February 13, 2023. This will be followed by a conference call at 4:30 p.m. EST to discuss the results and recent developments. The Hemopurifier, Aethlon's lead technology with FDA Breakthrough Device designation, is aimed at treating cancer and life-threatening viral infections, showcasing its importance in addressing significant health challenges.
Read more →AEMDAethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
Aethlon Medical, Inc. will present virtually at the Sequire Biotechnology Conference on February 2, 2023. Dr. Steven LaRosa, the Chief Medical Officer and Chief Scientific Officer, will lead the discussion on the company's innovative Hemopurifier technology. This device, designated as an FDA Breakthrough Device, aims to treat advanced cancer and severe viral infections. The conference will feature various biotechnology companies and is expected to attract numerous investors interested in the growing biotech market.
Read more →AEMDAethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer
Aethlon Medical has entered into a contract with NAMSA to manage clinical trials for its Hemopurifier device, aimed at treating cancer patients in the U.S. and Australia. The trials are set to begin in Australia, with Aethlon's CEO expressing confidence in NAMSA's experience in clinical studies. The Hemopurifier is designated as a Breakthrough Device by FDA, indicating its potential in treating advanced cancer and addressing life-threatening viral infections. However, the success of these trials is dependent on a variety of factors, including patient enrollment and the management of the trials.
Read more →AEMDAethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended Septemb
Read more →AEMDAethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2022
SAN DIEGO, Nov. 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter ended September 30, 2022, a
Read more →AEMDAethlon Medical, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors
Equity Incentive Plan by the Board of Directors: February 6, 2020 by the Stockholders: September 15, 2020 by the Board: March 24, 2022 Amended by the Board: July 15, 2022 by the Stockholders: September 15, 2022 1. General 1 2. Shares Subject to the Plan 1 3. Eligibility
Read more →AEMDAethlon Medical to Present at Two Investor Conferences in September
SAN DIEGO, Sept. 6, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that it will be presenting at two investor conference
Read more →AEMDAethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 9, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its first quarter ended June 30,
Read more →AEMDAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its first quarter ended June 30, 2022, at 4:15
Read more →AEMDAethlon Medical Announces Publication of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding of Seven COVID-19 Variants
SAN DIEGO, July 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced the publication of a peer-reviewed journal article in
Read more →AEMDAethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment
Approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study SAN DIEGO, July 11, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing produ
Read more →AEMDAethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022
SAN DIEGO, June 21, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022, at 4:15 p
Read more →AEMDAethlon Medical to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright Global Investment
Read more →AEMDAethlon Medical Publishes In Vitro Studies Demonstrating Hemopurifier Resin Binding of Seven Clinically Relevant COVID-19 Variants
Viral capture efficiency ranged from 53% to 89% for the seven COVID-19 variants tested SAN DIEGO, May 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseas
Read more →AEMDAethlon Medical, Inc. Appoints Angela Rossetti to Board of Directors
SAN DIEGO, March 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon") (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the appointment of Angela Rossetti to the Aethlon Boa
Read more →AEMDAethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022
SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter fiscal year 2022, ended Decem
Read more →AEMDAethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 9, 2021
SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter fiscal year 2022, ended Septe
Read more →AEMDAethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®
SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine descr
Read more →AEMDAethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs
SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (Nasdaq: PPD), a leading global co
Read more →AEMDAethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Glob
Read more →AEMDAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2021
SAN DIEGO, July 29, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2022, ended June 30, 2020, at 4:15 p.
Read more →AEMDAethlon Medical to Release Fourth Quarter Financial Results and Host Conference Call on June 24, 2021
SAN DIEGO, June 21, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2021, ended March 31, 2021, at 4:15
Read more →AEMDSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this " Agreement ") is dated as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is dated as of June 10, 2021, between Aethlon Medical, Inc., a Nevada corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors an
Read more →AEMDAethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, June 10, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a re
Read more →AEMDAethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier®
SAN DIEGO, June 3, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients t
Read more →AEMDAethlon Medical to Participate in Two Upcoming Healthcare Investor Conferences
SAN DIEGO, March 1, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that the company will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-
Read more →AEMDAethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 10, 2021
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its third quarter fiscal year 2021, ended December 31, 2020, at 4:15
Read more →AEMDNASDAQ: AEMD Investor Presentation January 2021 2 This investor presentation contains forward - looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limit
1 NASDAQ: AEMD Investor Presentation January 2021 2 This investor presentation contains forward - looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the ability to enroll patients in the Early Feasib
Read more →AEMDAethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Gu
Read more →AEMDAethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced that the company will participate in the virtual H.C. Wainwright
Read more →AEMDAethlon Medical Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer
SAN DIEGO, Dec. 16, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the first patient has been treated in the Company's first-i
Read more →AEMDAethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
SAN DIEGO, Nov. 3, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, announced today the appointment of Charles J. Fisher, Jr., M.D., as Chief Executive
Read more →AEMDAethlon Medical To Release Second Quarter Financial Results and Host Conference Call on October 28, 2020
SAN DIEGO, Oct. 19, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2021, ended September 30, 2020, at 4
Read more →AEMDAethlon Medical to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that Timothy C. Rodell, M.D., Chief Executive Officer, is s
Read more →AEMDAethlon Medical to Present at the LD Micro 500 Virtual Conference
SAN DIEGO, Aug. 27, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that CEO, Timothy C. Rodell, MD, is scheduled to present to
Read more →AEMDAethlon Medical Announces Collaboration with University of Pittsburgh on NIH Grant for Head and Neck Cancer
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in oncology and viral diseases announced today that the National Institute for Dental and Craniofacial Research (NIDCR), a unit
Read more →AEMDAethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 11, 2020
SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2021, ended June 30, 2020, at 4:15 pm
Read more →AEMDAethlon Medical Announces Fiscal Year Financial Results and Provides Corporate Update
SAN DIEGO, June 25, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2020 a
Read more →AEMDAethlon Medical Presents Hemopurifier® Data at the American Association for Cancer Research 2020 Annual Meeting
SAN DIEGO, June 22, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today released positive ex vivo data demonstrating the ability of a laboratory v
Read more →AEMDAethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a
Read more →AEMDAethlon Medical To Release Fourth Quarter Financial Results and Host Conference Call on June 25, 2020
SAN DIEGO, June 16, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2020, ended March 31, 2020, at 4:15p
Read more →AEMDAethlon Announces Issuance of European Patent for the Hemopurifier® in Cancer
SAN DIEGO, March 24, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that it has received European Patent No. 1,993,600 ("the '600 Patent") entitled "Extracorpo
Read more →AEMDSecurities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical Stock Expires
SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- On February 7, 2020, the Securities and Exchange Commission (SEC) issued an Order of Suspension of Trading (the "SEC Order"), temporarily suspending trading in Aethlon Medical, Inc. ("Aethlon" or the "Company")(NASDAQ:AEMD) stock for a per
Read more →AEMDSecurities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical (NASDAQ:AEMD) Stock
SAN DIEGO, Feb. 10, 2020 /PRNewswire/ -- (NASDAQ:AEMD) -- On February 7, 2020, the Securities and Exchange Commission (SEC) issued an Order of Suspension of Trading (the "SEC Order"), temporarily suspending trading in Aethlon Medical, Inc. ("Aethlon" or the "Company") stock for a
Read more →AEMDAethlon Medical To Release Third Quarter Financial Results and Host Conference Call on February 10, 2020
SAN DIEGO, Feb. 6, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its third quarter fiscal year 2020, ended December 31, 2019, at 4:15
Read more →AEMDAethlon Medical Announces Completion of $3.77 Million Registered Direct Offering
SAN DIEGO, Jan. 22, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD) ("Aethlon" or the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the completion of its previousl
Read more →AEMDAethlon Medical Announces $3.77 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, Jan. 17, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it has entered into definitive agreemen
Read more →AEMDAethlon Medical Announces Closing of $5 Million Public Offering
SAN DIEGO, Dec. 17, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the closing of the previously announced und
Read more →AEMDAethlon Medical Announces Pricing of $5 Million Public Offering
SAN DIEGO, Dec. 13, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the pricing of an underwritten public offeri
Read more →AEMDAethlon Medical To Release Second Quarter Financial Results and Host Conference Call on November 1, 2019
SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2020, ended September 30, 2019, at 4
Read more →AEMDAethlon Medical Announces FDA Approval Of IDE For Oncology Indications
SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that the FDA has approved its Investigational Device Exemption (IDE) application to initiate
Read more →AEMDAethlon Medical Receives Extension from Nasdaq to Regain Compliance with Continued Listing Requirements
SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that on October 2, 2019, Nasdaq granted Aethlon Medical an extension of time to regain compliance with the excha
Read more →AEMDAethlon Announces Collaboration to Identify Exosomes Involved in Cancer Progression and Treatment Resistance
SAN DIEGO, Sept. 24, 2019 /PRNewswire/ -- EXOSOME SCIENCES, a subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), announced a research collaboration to identify and characterize exosomes derived from patients with solid tumors such as pancreas cancer, as well as from families wit
Read more →AEMDAethlon Medical Receives National Cancer Institute Contract Award
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that the National Cancer Institute (NCI) has awarded the Company an SBIR Phase 2 contract for Topic 359, a sol
Read more →AEMDAethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 14, 2019
SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2020, ended June 30, 2019, at 4:15pm East
Read more →AEMDAethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement
SAN DIEGO and CARDIFF, Calif., July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD) and SeaStar Medical, Inc. today announced a cross-licensing agreement to jointly develop their respective medical devices to address the care and management of critically ill patients
Read more →AEMDAethlon Medical To Release Fiscal Year End Financial Results and Host Conference Call on July 1, 2019
SAN DIEGO, June 19, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for fiscal year 2019, ended March 31, 2019, at 4:15pm Eastern time on Mond
Read more →AEMDAethlon Medical Announces Collaboration With Prostate On-Site Project (POP), Host Of The Jerry Colangelo Sports Legend Golf Classic, To Engage With Participants For CTE Studies
PHOENIX, May 13, 2019 /PRNewswire/ -- Aethlon Medical Inc. (Nasdaq: AEMD) and its diagnostic subsidiary, Exosome Sciences, in collaboration with the Translational Genomics Research Institute (TGen) and the Prostate On-Site Project (POP), announced that Aethlon, TGen and POP will
Read more →AEMDAmendment to Convertible Notes This Amendment to Convertible Notes (this " Agreement "), effective as of
to Convertible Notes to Convertible Notes (this "Agreement"), effective as of May 6, 2019 (the "Effective Date"), is made by and among Aethlon Medical, Inc., a Nevada corporation (the "Company"), and the undersigned holders (collectively, the "Note Holders") of outstanding Co
Read more →AEMDAethlon Medical Releases Shareholder Update
Aethlon Medical Releases Shareholder SAN DIEGO, April 17, 2019 - Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following shareholder update authored by its CEO, Timothy C. Rodell, M.D. To Aethlon Medical, Inc. Shareholders: In December of last year, Aethlon complet
Read more →AEMDAethlon Medical, Inc. Announces Appointment of Lisa M. Boswell as Director, Quality Systems and Regulatory Affairs
SAN DIEGO, March 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device company focused on addressing critical unmet needs in global health, announces the appointment of Lisa M. Boswell, to the position of Director, Quality Systems and Regulato
Read more →AEMDAethlon Medical To Release Quarterly Financial Results and Host Conference Call on February 11, 2019
SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for the third quarter of fiscal year 2019, ended December 31, 2018, at 4:15
Read more →AEMDAethlon Announces Appointment of Timothy Rodell as Interim Chief Executive Officer
SAN DIEGO, Dec. 13, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today the appointment of Timothy C. Rodell, M.D., FCCP, as Interim Chief Executive Officer, effective as of December
Read more →AEMDAethlon Medical
SAN DIEGO, Nov. 27, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that it has received a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) to su
Read more →AEMDAethlon Medical Announces Second Quarter Fiscal Year 2019 Results
SAN DIEGO, Nov. 6, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced results for its fiscal second quarter ended September 30, 2018. Second Quarter Financial Results The Company's
Read more →AEMDAethlon Medical To Release Quarterly Financial Results and Host Conference Call on November 6, 2018
SAN DIEGO, Nov. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health today announced it will issue financial results for the second quarter fiscal year 2019 ended September 30, 2018 at 4:15pm easter
Read more →AEMDImage of Ebola viruses exiting host cells - Courtesy of NIAID NYC O NCOLOGY C ONFERENCE N ASDAQ : AEMD - M ARKET CAP : ~$20 M J IM J OYCE - F OUNDER & CEO O CTOBER 30, 2018 1 FORWARD LOOKING STATEMENTS The following pres
Image of Ebola viruses exiting host cells - Courtesy of NIAID NYC O NCOLOGY C ONFERENCE N ASDAQ : AEMD - M ARKET CAP : ~$20 M J IM J OYCE - F OUNDER & CEO O CTOBER 30, 2018 1 FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forw
Read more →AEMDAethlon Medical to Present at the NYC Oncology Conference
SAN DIEGO, Oct. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), an immunotherapeutic technology company focused on unmet needs in global health, today announced that its CEO, Jim Joyce, will present at the NYC Oncology Investor Conference on Tuesday, October 30, 201
Read more →AEMDAethlon Medical to Present at the 2018 BIO Investor Forum
SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), an immunotherapeutic technology company focused on unmet needs in global health, today announced that its CEO, Jim Joyce, will present at the 2018 BIO Investor Forum on Thursday, October 18, 2018 at 3:1
Read more →AEMDAethlon Medical Receives National Cancer Institute Award
SAN DIEGO, Sept. 18, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the National Cancer Institute (NCI) has awarded the Company a government grant (number 1R4
Read more →AEMDAethlon Medical Announces First Quarter Fiscal Year 2019 Results
SAN DIEGO, Aug. 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal first quarter ended June 30, 2018. First Quarter Financial Results At Ju
Read more →AEMDAethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2019 and Host Conference Call on August 8, 2018
SAN DIEGO, Aug. 2, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the first quarter fiscal year 2019 ended June 30, 2018 at 4:15
Read more →AEMDAethlon Medical Announces Issuance of Hemopurifier® Patent To Treat Life-Threatening Viruses
SAN DIEGO, July 23, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the issuance of U.S. Patent No. 10,022,483 ("the '483 Patent"). The '483 Patent protects key fea
Read more →AEMDGuy Cipriani Joins Aethlon Medical
SAN DIEGO, June 25, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independ
Read more →AEMDAethlon Medical Announces Fiscal 2018 Results
SAN DIEGO, June 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal year ended March 31, 2018. Recent Corporate Developments During the fisc
Read more →AEMDAethlon Medical To Release 2018 Fiscal Year End Financial Results and Host Conference Call on June 8, 2018
SAN DIEGO, May 31, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the fiscal year ended March 31, 2018 at 4:15pm Eastern Time on
Read more →AEMDAethlon Medical to Release Third Quarter Fiscal Year 2018 Financial Results and Host Conference Call on February 1, 2018
SAN DIEGO, Jan. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue third quarter results for the fiscal year ended March 31, 2018 at 4:15 pm eastern t
Read more →AEMDAethlon Medical Announces Allowance of U.S. Patent that Broadens Protection for the Aethlon Hemopurifier® to Treat Viral Infections
SAN DIEGO, Jan. 18, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application Number 14
Read more →AEMDSabrina Martucci Johnson Joins Aethlon Medical's Board of Directors
Sabrina Martucci Johnson Joins Aethlon Medical's Board of Directors SAN DIEGO, CA, January 10, 2018 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Sabrina Mar
Read more →AEMDAethlon Medical Names Dr. Charles J. Fisher Chairman of the Board
SAN DIEGO, Nov. 29, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Charles ("Chuck") J. Fisher, Jr., MD as Chairman of its Board of Directors.
Read more →AEMDDr. Charles J. Fisher, Jr. Joins Aethlon Medical
SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Charles ("Chuck") J. Fisher, Jr., MD to its Board of Directors and to its Audi
Read more →AEMDAethlon Medical Announces Fiscal 2018 Second Quarter Results
SAN DIEGO, Nov. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal second quarter ended September 30, 2017. Key Recent Developments EAP – I
Read more →AEMDAethlon Medical to Release Financial Results for the Second Quarter Fiscal Year 2018 and Host Conference Call on November 2, 2017
SAN DIEGO, Oct. 30, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the second quarter fiscal year 2018 ended September 30, 2017
Read more →AEMDAethlon Medical Announces Large-Scale Production Collaboration
SAN DIEGO, Oct. 16, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has established a collaboration with iBio, Inc. (NYSE AMERICAN: IBIO) to support potenti
Read more →AEMDAethlon Medical to Present at the 2017 BIO Investor Forum
SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that its Chairman and CEO, Jim Joyce, will be a featured presenter at the 2017 BIO Investor Forum
Read more →AEMDAethlon Medical Announces Compliance With Nasdaq Listing Criteria
SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that Nasdaq has formally notified the Company that it has demonstrated compliance with all appli
Read more →AEMDAethlon Medical Announces Pricing of $6 Million Public Offering
SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announces the pricing of a public offering of an aggregate of 5,454,546 units. Each unit is comprised of one share
Read more →AEMDAethlon Medical Receives Expedited Access Pathway Designation from FDA to Accelerate U.S. Access to the Hemopurifier® as a Treatment for Life-Threatening Viruses
SAN DIEGO, Sept. 12, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has received an Expedited Access Pathway (EAP) designation from the United States Food
Read more →AEMDImage of Ebola viruses exiting host cells - Courtesy of NIAID 1 The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether
Image of Ebola viruses exiting host cells - Courtesy of NIAID 1 The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introd
Read more →AEMDDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Aethlon Medical, Inc. Senior Director Regulatory Affairs 224 Airport Parkway, Suite 250 Re:
Read more →AEMDAethlon Medical to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017
SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced that its Chairman and CEO, Jim Joyce, will be a featured presenter at the 19th Annual Rodman & Re
Read more →AEMDAethlon Medical Announces Fiscal 2018 First Quarter Results
SAN DIEGO, Aug. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal first quarter ended June 30, 2017. The Company disclosed that it has fin
Read more →AEMDAethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2018 and Host Conference Call on August 10, 2017
SAN DIEGO, Aug. 3, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the first quarter fiscal year 2018 ended June 30, 2017 at 4:15
Read more →AEMDAethlon Medical Announces the Grant of a U.S. Patent Protecting Methods of Capturing MHC Antigen Associated Exosomes
SAN DIEGO, July 19, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the United States Patent and Trademark Office has granted U.S. Patent Number 9,707,333 (the
Read more →AEMDAethlon Medical Announces Fiscal 2017 Results
SAN DIEGO, June 28, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal year ended March 31, 2017. On March 13, 2017, Aethlon disclosed that it
Read more →AEMDAethlon Medical To Release 2017 Fiscal Year End Financial Results and Host Conference Call on June 28, 2017
SAN DIEGO, June 26, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced it will issue financial results for the fiscal year ended March 31, 2017 at 4:15pm eastern time
Read more →AEMDImage of Ebola viruses exiting host cells - Courtesy of NIAID BIO I NTERNATIONAL C ONVENTION J IM J OYCE - C HAIRMAN , CEO N ASDAQ - AEMD / J UNE 21, 2017 1 FORWARD LOOKING STATEMENTS The following presentation may conta
Image of Ebola viruses exiting host cells - Courtesy of NIAID BIO I NTERNATIONAL C ONVENTION J IM J OYCE - C HAIRMAN , CEO N ASDAQ - AEMD / J UNE 21, 2017 1 FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statem
Read more →AEMDAethlon Medical To Present Clinical Study Results at The BIO International Convention
SAN DIEGO, June 14, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that Company Chairman and CEO, Jim Joyce will present at the 2017 BIO International Convention (
Read more →AEMDAethlon Medical, Inc., Announces Upcoming Presentation and Webcast at the LD Micro Invitational Conference on June 6, 2017
SAN DIEGO, June 06, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced that James Joyce, CEO, will be presenting an overview of the company's clinical strategy to comba
Read more →AEMDAethlon to Present at the LD Micro Invitational Conference on June 6, 2017
SAN DIEGO, May 24, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced James Joyce, CEO, will be a featured presenter at the LD Micro Invitational on Tuesday, June 6, 20
Read more →AEMDAethlon Medical Discloses Tech Nation Interview On National Public Radio
SAN DIEGO, April 4, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, disclosed today that an interview conducted with Company CEO Jim Joyce on the weekly Tech Nation radio program i
Read more →AEMDAethlon Medical Announces The Conclusion Of Hemopurifier Clinical Study
SAN DIEGO, March 13, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the company has concluded an FDA-approved feasibility study designed to assess the safety
Read more →AEMDA e thlon Medical, Inc . Nasdaq: AEMD ROTH INVESTOR CONFERENCE MARCH 14, 2017 Jim Joyce Chairman, CEO 1 FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking
A e thlon Medical, Inc . Nasdaq: AEMD ROTH INVESTOR CONFERENCE MARCH 14, 2017 Jim Joyce Chairman, CEO FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including wh
Read more →AEMDAethlon Medical To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 14, 2017
SAN DIEGO, March 8, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 29th Annual Growth Stock Conference in Dana Point, CA at 10:30 a.m. PT (1:30 p.m. ET) on Tuesday, March
Read more →AEMDAethlon Medical Announces the Grant of a European Patent Protecting Methods of Quantifying Exosomes
SAN DIEGO, March 1, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that the European Patent Office has granted European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES." In recent years, exosomes have emerged as a si
Read more →AEMDAethlon Medical CEO Note: Bill Gates on the Threat of Bioterrorism
SAN DIEGO, Feb. 24, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. In a chilling address at the Munich Security Conference last Saturday, Bill Gates warned world leaders that a genetically
Read more →AEMDAethlon Medical Reports Results of Cytomegalovirus, Epstein-Barr and Herpes Simplex Virus Studies
SAN DIEGO, Feb. 22, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of a study that validated the ability of the Aethlon Hemopurifier® to capture latent viral pathogens that are associated with increased mortality in immune-suppressed sepsis
Read more →AEMDAethlon Medical Announces Fiscal 2017 Third Quarter Results
SAN DIEGO, Feb. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal third quarter year ended December 31, 2016. Aethlon's lead therapeutic can
Read more →AEMDAethlon Medical To Host Third Quarter Fiscal 2017 Investor Call On February 10, 2017
SAN DIEGO, Feb. 6, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its Third Quarter Fiscal 2017 investor conference call and webcast on Friday, February 10, 2017 at 4:30 p.m. Eastern Time. The call and webcast will follow the release
Read more →AEMDResearchers Announce Plans for Study of Candidate Blood Test to Detect Chronic Traumatic Encephalopathy (CTE) in Former NFL Players
HOUSTON and SAN DIEGO, Jan. 25, 2017 /PRNewswire/ -- Researchers with Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company, today announced plans to initiate a clinical study involving retired NFL players and a
Read more →AEMDCEO Note - Clinical Study Update and a Review of 2016 Accomplishments
SAN DIEGO, Jan. 11, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. To Our Shareholders, During the course of 2016, our primary mission was the clinical advancement of our Hemopurifier® in
Read more →AEMDPassage of the 21st Century Cures Act and its Potential Implications on Biodefense
SAN DIEGO, Dec. 21, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. Last week, President Obama signed the 21st Century Cures Act into law. The $6.3 billion bill establishes new rules that d
Read more →AEMDAethlon Announces Initiation of Sepsis-Related Virus Study
SAN DIEGO, Dec. 15, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has initiated a research study to validate the ability of the Aethlon Hemopurifier® to capture viruses that are associated with increased mortality in immune-suppressed sepsis p
Read more →AEMDAethlon Medical Announces Fiscal 2017 Second Quarter Results
SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal second quarter year ended September 30, 2016. Aethlon's lead therapeutic c
Read more →AEMDAethlon Medical To Host Second Quarter Fiscal 2017 Investor Call On November 10, 2016
SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its Second Quarter Fiscal 2017 investor conference call and webcast on Thursday, November 10, 2016 at 4:30 p.m. Eastern Time. The call and webcast will follow the rele
Read more →AEMDAethlon Medical Achieves DARPA Milestones, Including Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Validation
SAN DIEGO, Oct. 13, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has completed multiple milestone achievements under a contract with the Defense Advanced Research Projects Agency (DARPA), including a milestone validation that the Aethlon Hemo
Read more →AEMDAethlon Medical Announces Corporate Update Presentation At Next Week
SAN DIEGO, Oct. 12, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, will be presenting a corporate update at the 2016 Bio Investor Forum in San Francisco, CA at 6:30 p.m. ET (3:30 p.m. PT) on Tuesday, October 18, 2016.
Read more →AEMDAethlon Medical Updates Corporate Presentation Schedule
SAN DIEGO, Sept. 20, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced changes to its corporate presentation schedule over the coming month. On September 6th, the Company disclosed that its Chairman and CEO, Jim Joyce, would be presenting at the Aegis Cap
Read more →AEMDAethlon Medical To Present At The Rodman & Renshaw 18th Annual Global Investment Conference On September 13, 2016
SAN DIEGO, Sept. 12, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, and Jim Frakes, Chief Financial Officer, will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference in New York, NY at 2:10 p
Read more →AEMDThe Dilemma in Funding Zika and Other Pandemic Therapies
SAN DIEGO, Sept. 9, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. After a seven-week vacation, the U.S. Congress and Senate returned to work on Tuesday and immediately restarted the fight
Read more →AEMDAethlon Medical Announces Upcoming September Investor And Industry Conferences
SAN DIEGO, Sept. 6, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today its upcoming conference schedule for the month of September. Aethlon management will be presenting at the following conferences and is available for one-on-one meetings at the events. A
Read more →AEMDAethlon Medical Announces Fiscal 2017 First Quarter Results
SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal first quarter year ended June 30, 2016. Aethlon's lead therapeutic candida
Read more →AEMDAethlon Medical Announces Zika Virus Data
SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika vi
Read more →AEMDAethlon Medical To Host First Quarter Fiscal 2017 Investor Call On August 11, 2016
SAN DIEGO, Aug. 9, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its First Quarter Fiscal 2017 investor conference call and webcast on Thursday, August 11, 2016 at 4:30 p.m. Eastern Time. The call and webcast will follow the release
Read more →AEMDAethlon Medical Announces Fiscal 2016 Results
SAN DIEGO, June 29, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a leading developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal year ended March 31, 2016. "Over the past year we achieved a broad
Read more →AEMDAethlon Medical Announces $12.5 Million At The Market Program
SAN DIEGO, June 28, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (the "Company") (Nasdaq: AEMD), a leading developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that it has filed a prospectus supplement under which it may sell up to $1
Read more →AEMDAethlon Medical Joins Russell Microcap® Index
SAN DIEGO, June 27, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has been added to the Russell Microcap® Index. The annual reconstitution of Russell U.S. Indexes became effective with the opening of the U.S. markets for trading today. Member
Read more →AEMDAethlon Medical to Host Fourth Quarter and Full Year Fiscal 2016 Investor Call On June 29, 2016
SAN DIEGO, June 27, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its Fourth Quarter and Full Year Fiscal 2016 investor conference call and webcast on Wednesday, June 29, 2016 at 4:30 p.m. Eastern Time. The call and webcast will fol
Read more →AEMDAethlon Medical Set To Join Russell Microcap® Index
SAN DIEGO, June 22, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has been added to the preliminary list of new additions to join the Russell Microcap Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after t
Read more →AEMDAethlon Medical Announces Issuance Of Exosome Capture Patent
SAN DIEGO, June 14, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that U.S. Patent Number 9,364,601 (the "601 Patent"), related to methods for capturing an exosome from a patient, has been issued to the Company by the United States Patent and Trademar
Read more →AEMDA e thlon Medical, Inc . Nasdaq : AEMD BIO International Convention San Francisco
A e thlon Medical, Inc . Nasdaq : AEMD BIO International Convention San Francisco June 7, 2016 Jim Joyce Chairman, CEO FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertaint
Read more →AEMDAethlon Medical To Present Cancer And Infectious Disease Initiatives, As Well As Chronic Traumatic Encephalopathy (CTE) Candidate Biomarker Discovery At Tomorrow
SAN DIEGO, June 6, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, will be presenting tomorrow (June 7th) at the BIO International Convention being held at Moscone Center in San Francisco, California. The presentation,
Read more →AEMDA e thlon Medical, Inc . Nasdaq : AEMD SACHS IMMUNO - ONCOLOGY BD&L INVESTMENT FORUM JUNE 3, 2016 Jim Joyce Chairman, CEO 1 FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and ot
A e thlon Medical, Inc . Nasdaq : AEMD SACHS IMMUNO - ONCOLOGY BD&L INVESTMENT FORUM JUNE 3, 2016 Jim Joyce Chairman, CEO FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncerta
Read more →AEMDAethlon Medical To Present At 2nd Annual Sachs Associates Immuno-oncology: BD&L And Investment Forum On June 3, 2016
SAN DIEGO, June 1, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum (http://www.sachsforum.com/2nd-immuno-oncology-bdl-and-
Read more →AEMDAethlon Medical (AEMD) CEO Note: Hemopurifier Clinical Progression, USA Today on the Next Zika, Combating Bioterror & Pandemic Threats
SAN DIEGO, May 2, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. At present, we are conducting the first FDA approved study of Hemopurifier® therapy as a candidate broad-spectrum counterme
Read more →AEMDAethlon Medical Discloses Hemopurifier® Clinical Trial and Manufacturing Advancements
SAN DIEGO, March 31, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), reported that the recently appointed principal investigator of its FDA approved clinical study in Houston, Texas, has completed a six-treatment protocol of Hemopurifier therapy in an enrolled patient
Read more →AEMDAethlon Medical, Inc. Reports Annual Meeting Results
SAN DIEGO, March 30, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of its Annual Meeting of Stockholders completed on March 29, 2016 in San Diego, California. All proposed motions were approved by stockholders. Based on the report from the
Read more →AEMDAethlon Medical To Present At Roth Capital Partners 28th Annual Growth Stock Conference On March 16, 2016
Aethlon Hemopurifier. SAN DIEGO, March 9, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 28th Annual Growth Stock Conference in Laguna Niguel, CA at 10:30 a.m. PT (1:30
Read more →AEMDAethlon Medical To Present At 4th Annual Sachs Cancer Bio Partnering & Investment Forum On February 24, 2016
Aethlon Hemopurifier. (PRNewsFoto/Aethlon Medical, Inc.) SAN DIEGO, Feb. 18, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 4th Annual Sachs Cancer Bio Partnering & Investment Forum at the Ne
Read more →AEMDAethlon Medical to Present at Source Capital Group
Aethlon Hemopurifier. (PRNewsFoto/Aethlon Medical, Inc.) SAN DIEGO, Feb. 5, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference in
Read more →AEMDAethlon Medical Announces Fiscal 2016 Third Quarter Results
Aethlon Hemopurifier. (PRNewsFoto/Aethlon Medical, Inc.) SAN DIEGO, Feb. 4, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the third quarter of fisc
Read more →AEMDAethlon Medical Announces Dengue Virus Study Approval, Chikungunya Virus Capture Data and Completion of U.S. Principal Investigator Training
Aethlon Hemopurifier. (PRNewsFoto/Aethlon Medical, Inc.) SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that a human treatment study entitled: "A Clinical Safety Study of the Aethlon Hemopurifier® in Patients with Dengue Virus Infec
Read more →AEMDAethlon Medical to Present at the 18th Annual BIO CEO & Investor Conference
Aethlon Hemopurifier. SAN DIEGO, Feb. 1, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the BIO CEO & Investor Conference in New York, NY at 3:30 p.m. ET on Tuesday, February 9, 2016. The presen
Read more →AEMDAethlon Medical To Host Third Quarter Fiscal 2016 Investor Call on February 4, 2016
Aethlon Hemopurifier. (PRNewsFoto/Aethlon Medical, Inc.) SAN DIEGO, Jan. 29, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its Third Quarter
Read more →AEMDAethlon Medical Announces Fiscal 2016 Second Quarter Results
Aethlon Hemopurifier. SAN DIEGO, Nov. 16, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the second quarter of fiscal 2016 ended September 30, 2015.
Read more →AEMDA e thlon Medical, Inc . Therapeutic Partnering Opportunities IN3 Medical Device Summit
A e thlon Medical, Inc . Therapeutic Partnering Opportunities IN3 Medical Device Summit November 11, 2015 Jim Joyce Chairman, CEO FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and
Read more →AEMDAethlon Medical to Participate in the IN3 Medical Device 360 Summit
Aethlon Hemopurifier. SAN DIEGO, Nov. 10, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that Jim Joyce, Chairman and CEO, will be presenting at the IN3 Medical
Read more →AEMDAethlon Medical To Host Second Quarter Fiscal 2016 Investor Call on November 16, 2015
Aethlon Hemopurifier. SAN DIEGO, Oct. 26, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its Second Quarter Fiscal 2016 investor conference ca
Read more →AEMDAethlon Medical Extends Contract with the Defense Advanced Research Projects Agency
SAN DIEGO, Sept. 28, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it has entered into an extension of its contract with the Defense Advanced Research Projects Agency, or DARPA, part of the Department of Defense. The Company originally entered in
Read more →AEMDFORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfull
FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced ; market acceptance of the A e th
Read more →AEMDAethlon Medical to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
SAN DIEGO, Sept. 2, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the Rodman & Renshaw 17th Annual Global Investment Conference in New York, NY at 9:35 a.m. ET on Thursday, September 10, 2015. T
Read more →AEMDAethlon Medical to Ring the Nasdaq Stock Market Closing Bell on July 24th
SAN DIEGO, July 21, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company will ring the Nasdaq Stock Market closing bell on Friday, July 24, 2015 in hon
Read more →AEMDAethlon Medical Begins Trading on the Nasdaq Capital Market
SAN DIEGO, July 13, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's common stock commenced trading on the Nasdaq Capital Market under the symbol
Read more →AEMDAethlon Medical Announces Nasdaq Capital Market Listing Approval
SAN DIEGO, July 8, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's application to list its common stock on the Nasdaq Capital Market has been app
Read more →AEMDAethlon Medical Announces $6 Million Equity Investment
SAN DIEGO, June 24, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that it entered into a definitive $6 million stock purchase agreement. The per share purchase pr
Read more →AEMDA Case Study using Lectin - Affinity Plasmapheresis in the Treatment of Ebola Virus Disease Rod Kenley President, Aethlon Medical, Inc. 33rd Vicenza Course on Critical Care Nephrology
A Case Study using Lectin - Affinity Plasmapheresis in the Treatment of Ebola Virus Disease Rod Kenley President, Aethlon Medical, Inc. 33rd Vicenza Course on Critical Care Nephrology June 12, 2015 Lectin Symbol Lectin name Source Ligand Mannose Binding Lectins ConA Concanavalin
Read more →AEMDAethlon Medical Discloses Upcoming Presentations
SAN DIEGO, June 11, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that its President Rod Kenley will give a presentation on June 12th at the 33rd Annual Vicenza
Read more →AEMDAethlon Medical Announces Resignation of Inside Director to Comply with NASDAQ Corporate Governance Requirements
SAN DIEGO, June 9, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that in order to support the Company's application to list on the Nasdaq Capital Market, Dr. Rich
Read more →AEMDAethlon Medical to Present at the BIO International Convention
SAN DIEGO, June 5, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that Chairman and CEO Jim Joyce will give a corporate presentation at the BIO International Conv
Read more →AEMDAethlon Medical Expands Clinical Research Studies to Include Chikungunya Virus
SAN DIEGO, June 4, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that it has entered into an agreement with the National Institute of Virology (NIV) to begin test
Read more →AEMDAethlon Medical to Present at SeeThruEquity Microcap Investor Conference
SAN DIEGO, May 26, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the SeeThruEquity 4th Annua
Read more →AEMDAethlon Medical Announces Health Canada Approval of Ebola Treatment Protocol
SAN DIEGO, May 13, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to
Read more →AEMDAethlon Medical Announces Institutional Review Board Approval of Multi-Indication Cancer Study
SAN DIEGO, May 12, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that the Institutional Review Board (IRB) of the University of California, Irvine (UCI) has
Read more →AEMDAethlon Medical Announces Withdrawal of S-1 Registration Statement
SAN DIEGO, May 4, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that on Friday, May 1, 2015, it filed with the Securities and Exchange Commission (th
Read more →AEMDAethlon Medical Discloses Presentation of Preliminary CTE Related Study Results
SAN DIEGO, April 16, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that Dr. Robert Stern, professor of neurology, neurosurgery, and anatomy and neurob
Read more →AEMDAethlon Medical Announces Cancer Clinical Trial Agreement
SAN DIEGO, April 15, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has entered into an investigator-initiated clinical trial agreement with the Unive
Read more →AEMDAethlon Medical Announces Effectiveness of Reverse Stock Split
SAN DIEGO, April 14, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that its previously disclosed 1-for-50 reverse stock split is effective as of today, April
Read more →AEMDAethlon Medical Announces Ebola Humanitarian Use Device Submission to the FDA
SAN DIEGO, April 9, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has submitted a Humanitarian Use Device submission to the United States Food and D
Read more →AEMDAethlon Medical Announces Reverse Stock Split and Nasdaq Listing Submission
SAN DIEGO, April 8, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it will implement a 1-for-50 reverse split of its common stock. The implementation of
Read more →AEMDAethlon Medical Discloses Head and Neck Cancer Collaboration
SAN DIEGO, April 2, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, disclosed today that its majority owned subsidiary Exosome Sciences, Inc. has entered into a research col
Read more →AEMDUpdate - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference
SAN DIEGO, March 6, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Aethlon Medical CEO, is now scheduled to present a corporate overvie
Read more →AEMDAethlon Medical to Present at the 27th Annual ROTH Conference
SAN DIEGO, March 4, 2015 /PRNewswire/ --Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Aethlon Medical CEO, is scheduled to present a corporate overview at
Read more →AEMDAethlon Medical Announces First Patient Completes Hemopurifier® Clinical Study Protocol
SAN DIEGO, Feb. 26, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that the first patient enrolled in the Company's FDA approved feasibility study has compl
Read more →AEMDAethlon Medical, Inc. - CTE Data Presentation at the Upcoming 2015 TBI Conference
SAN DIEGO, Feb. 24, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers
Read more →AEMDAethlon Medical, Inc. - A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier®
SAN DIEGO, Feb. 12, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers
Read more →AEMDAethlon Medical, Inc. - The Launch of a Clinical Program That Re-Thinks the Treatment of Viral Pathogens
SAN DIEGO, Feb. 5, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers
Read more →AEMDAethlon Medical to Present at Biotech Showcase 2015
SAN DIEGO, Jan. 8, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the Biotech Showcase 2015 Co
Read more →AEMDAethlon Medical Announces Approval of Ebola Treatment Protocol
SAN DIEGO, Jan. 2, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that the United States Food and Drug Administration (FDA) has approved a clinical protocol to tr
Read more →AEMDAethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study
SAN DIEGO, Dec. 11, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopuri
Read more →AEMDAethlon Medical® Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients
SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today reported final clinical outcomes, including rapid virologic response (RVR) and sustained virologic re
Read more →AEMDAethlon Medical Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States
SAN DIEGO, Nov. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today announced the first shipment of Hemopurifier® therapy as a candidate to treat future Ebola vi
Read more →AEMDAethlon Medical Announces $3.3 Million Equity Investment
SAN DIEGO, Nov. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), announced today that it has entered into a definitive agreement to raise approximately $3.3 million at a price of $0.30 per unit. The investment is being made by one institutional healthcare focused inve
Read more →AEMDEbola Patient Who Received Aethlon Hemopurifier® Therapy Has Been Discharged From Hospital
SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that an Ebola patient who received Hemopurifier® therapy has been reported to have
Read more →AEMDTime Magazine Names The Aethlon Hemopurifier® One of the 25 Best Inventions of 2014
SAN DIEGO, Nov. 21, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® has been named one of the 25 best inventions of 2014
Read more →AEMDAethlon Medical Discloses Expanded Access "Emergency Use" Pathway To Treat Ebola in the United States
SAN DIEGO, Nov. 19, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that it will provide Hemopurifier® therapy under FDA expanded access "emergency use
Read more →AEMDAethlon Medical to Present at Tomorrow
SAN DIEGO, Nov. 11, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at
Read more →AEMDAethlon Medical Announces Presentation of Ebola Treatment Data This Friday, November 14th at the ASN Annual Meeting
SAN DIEGO, Nov. 10, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that treatment data resulting from the administration of Hemopurifier® therapy to a
Read more →AEMDAethlon Medical Announces Undetectable Ebola Virus in Patient Treated with Hemopurifier® Therapy
SAN DIEGO, Nov. 6, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that officials at Frankfurt University Hospital have reported undetectable virus in
Read more →AEMDAethlon Medical Discloses Ebola Treatment Pathways in the United States
SAN DIEGO, Oct. 29, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that it will provide Hemopurifier® therapy under FDA compassionate use access provi
Read more →AEMDAethlon Medical Announces First Treatment of an Ebola Patient
SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. T
Read more →AEMDAethlon Medical and Exosome Sciences Announce Clinical Collaboration with Boston University CTE Center To Advance Diagnostic Candidate to Detect CTE in Former NFL Players
SAN DIEGO, PRINCETON, N.J. and BOSTON, Sept. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical collaboration with the Boston University (BU) CTE Center has been establis
Read more →AEMDAethlon Medical Announces Dengue Virus Treatment Agreement
SAN DIEGO, Sept. 24, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into an agreement with Qualtran,
Read more →AEMDJIM JOYCE CHAIRMAN, CEO EXOSOMES 2014 September 18 & 19, 2014 San Diego, California Extracorporeal Clearance of Tumor - Secreted Exosomes ; An Adjunct Strategy to Improve Cancer Treatment Outcomes 1 FORWARD LOOKING STATE
JIM JOYCE CHAIRMAN, CEO EXOSOMES 2014 September 18 & 19, 2014 San Diego, California Extracorporeal Clearance of Tumor - Secreted Exosomes ; An Adjunct Strategy to Improve Cancer Treatment Outcomes FORWARD LOOKING STATEMENTS The following presentation may contain predictions, est
Read more →AEMDAethlon Medical Receives Notice of DARPA Contract Renewal
SAN DIEGO, Sept. 22, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that the Defense Advanced Research Projects Agency (D
Read more →AEMDAethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit
SAN DIEGO and PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, and its diagnostic subsidiary, Exosome Scie
Read more →AEMDAethlon Medical, Inc. Launches Digital Corporate Communication Channels
SAN DIEGO and NEW YORK, Sept. 10, 2014 /PRNewswire/ -- Aethlon Medical, Inc., (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today a suite of online corporate comm
Read more →AEMDAethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform
SAN DIEGO and PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that
Read more →AEMDAethlon Medical Announces Receipt of IRB Approval to Initiate Hemopurifier® Clinical Studies
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal revie
Read more →AEMDAethlon Medical (AEMD) CEO Note: A Novel Strategy To Address Ebola
SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. ESI Logo. (PRNewsFoto/Aethlon Medical, Inc.) (PRNewsFoto/) The current ebola outbreak in West Africa demonstrates the urge
Read more →AEMDAethlon Medical Announces Online Access to Infectious Disease and Cancer Therapy Presentation
SAN DIEGO, June 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wal
Read more →AEMDAethlon Medical to Present at The Wall Street Analyst Forum
SAN DIEGO, June 17, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Execu
Read more →AEMDAethlon Medical® Announces Definitive Agreement with DaVita Clinical Research and Site Location and Principal Investigator of Hepatitis C Virus (HCV) Clinical Study
SAN DIEGO, May 20, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into a definitive agreem
Read more →AEMDAethlon Medical (AEMD) CEO Note: Cancer Treatment Discovery, Exosomes Transport Pharmaceutical Industry Targets
SAN DIEGO, May 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. ESI Logo. (PRNewsFoto/Aethlon Medical, Inc.) (PRNewsFoto/) The discovery that our Hemopurifer® captures tumor-secreted exo
Read more →AEMDAethlon Medical (AEMD) CEO Note: Cancer Therapy Publication References Aethlon Medical
SAN DIEGO, April 22, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. Aethlon Hemopurifier. (PRNewsFoto/Aethlon Medical, Inc.) (PRNewsFoto/) When we initiated our first exosome research prog
Read more →AEMDAethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target
SAN DIEGO, March 19, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the
Read more →AEMDAethlon Medical and Exosome Sciences Announce Brain Research Discoveries
SAN DIEGO, March 5, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disor
Read more →AEMDAethlon Medical® Announces Agreement with DaVita Clinical Research®
SAN DIEGO, Feb. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in pr
Read more →AEMDAethlon Medical to Present at Biotech Showcase Investor Conference
SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Execut
Read more →AEMDAethlon Medical to Present at SeeThruEquity Investor Conference
SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Company Chairman and CEO, Jim Joyce will present a corporate overview at the SeeThruEquity Investor Conference on November 12th at 10:30 am Eastern Standard Time (EST). Mr. Joyce's p
Read more →AEMDAethlon Medical (AEMD) Note: Grand Opening of Exosome Sciences Subsidiary on November 12th at 6:30pm Eastern
SAN DIEGO, Nov. 4, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) ESI Logo. (PRNewsFoto/Aethlon Medical, Inc.) (PRNewsFoto
Read more →AEMDAethlon Medical (AEMD) Note: Cancer Immunotherapy Article, Introduction to Dr. Douglas Taylor
SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) ESI Logo. (PRNewsFoto/Aethlon Medical, Inc.) (PRNewsFot
Read more →AEMDAethlon Medical (AEMD) Note: Clinical Partnering Programs, Manufacturing Optimization and Ramp-Up, Exosome Sciences Grand Opening
SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO) ESI Logo. (PRNewsFoto/Aethlon Medical, Inc.) (PRNewsFoto/)
Read more →AEMDAethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Defense Advanced Research Projec
Read more →AEMDAethlon Medical Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc.
SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Dr. Cicek Gercel-Taylor has been appointed Clinical Research Director of Exosome Sciences, Inc. (ESI), a wholly-owned diagnostic subsidiary of Aethlon Medical. In this role, Dr. Ge
Read more →AEMDAethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
SAN DIEGO, Sept. 13, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Dr. Douglas Taylor has accepted the position of Chief Scientific Officer at Exosome Sciences, Inc. (ESI), a wholly owned diagnostic subsidiary of Aethlon Medical. Dr. Taylor is cre
Read more →AEMDAethlon Medical Announces Launch of Exosome Sciences Subsidiary
SAN DIEGO, Sept. 12, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today announced the formal launch of Exosome Sciences, Inc. (ESI), a wholly-owned subsidiary previously established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression
Read more →AEMDAethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit
SAN DIEGO, Sept. 5, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Company Chairman and CEO, Jim Joyce has accepted an invitation to present at the Exosomes and Circulating Biomarkers 2013 Summit on September 12th. Mr. Joyce's presentation is entit
Read more →AEMDAethlon Medical Announces European Patent to Remove Viruses From Blood
SAN DIEGO, July 25, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that the European Patent Office has provided the Company with a Decision To Grant A Patent entitled "METHOD OF REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS". The Europea
Read more →AEMDAethlon Medical Announces the Appointment of Chetan S. Shah, M.D. to its Board of Directors
SAN DIEGO, July 12, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the appointment of Chetan S. Shah, M.D. to
Read more →AEMDAethlon Medical Announces FDA Approval of IDE to Treat Hepatitis C (HCV) Patients
SAN DIEGO, June 25, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that the United States Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aeth
Read more →AEMDAethlon Medical (AEMD) Note: An Update on the Clinical Status of the Aethlon Hemopurifier® in Hepatitis-C Care
SAN DIEGO, May 7, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. Through the publication of CEO notes, I seek to provide shareholders and other interested parties with a level of corporate
Read more →AEMDAethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
SAN DIEGO, April 18, 2013 /PRNewswire/ --Aethlon Medical, Inc. (OTCBB: AEMD), disclosed that a poster presentation entitled: "Extracorporeal Exosome Removal: A Therapeutic Strategy to Address an Evolutionary Survival Mechanism Shared by Cancer and Infectious Viral Pathogens," is
Read more →AEMDAethlon Medical (AEMD) Note: New Government Contract, Resubmission of IDE to Treat Hepatitis C (HCV), Biothreat Legislation Signed into Law by President Obama
SAN DIEGO, April 16, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. As disclosed in yesterday's SEC form 8-K submission, we entered into a subcontract agreement with Battelle Memorial Insti
Read more →AEMDAethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
SAN DIEGO, Feb. 28, 2013 /PRNewswire/ --Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. I recently attended a healthcare related event that featured a panel discussion comprised of life science bankers and ventu
Read more →AEMDAethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTC: AEMD), announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing. LINK: www.retailinvestorconferences.com> red "register/ watch event now" button
Read more →AEMDAethlon Medical, Inc. to Webcast, Live, at Retail InvestorConferences.com on February 7th
NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTC: AEMD), announced today that Chairman and Chief Executive officer, James Joyce will present at RetailInvestorConferences.com. DATE: February 7, 2013 TIME: 2:00PM EST LINK: www.retailinvestorconferences.com > red "
Read more →AEMDAethlon Medical (AEMD) Note: Since September 30th, 2011 / Thank You Shareholders
SAN DIEGO, Feb. 5, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. In our quest to innovate life-saving therapeutics, we have persevered through untold challenges to create a single medical
Read more →AEMDAethlon Medical Discloses CEO Interview
SAN DIEGO, Jan. 29, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today disclosed that a recent interview our Chairman and CEO, Jim Joyce participated in with the UT San Diego radio network is now available on-line. Mr. Joyce was interviewed on the Brian Britt Show w
Read more →AEMDAethlon Medical (AEMD) Note: Extracorporeal Methods to Reduce Inflammation in Sepsis
SAN DIEGO, Jan. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. Yesterday, our President Rod Kenley presented an informative review of extracorporeal medical device strategies to treat s
Read more →AEMDAethlon Medical To Present Today At The 15th International Conference On Dialysis
SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), announced that President, Rod Kenley will present today at the 15th International Conference on Dialysis being hosted by the Renal Research Institute. Mr. Kenley's presentation is entitled: "Extracorpor
Read more →AEMDAethlon Medical Announces the Appointment of Laszlo Radvanyi, Ph.D. to its Scientific Advisory Board
SAN DIEGO, Jan. 17, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that Laszlo Radvanyi, Ph.D., an Associate
Read more →AEMDAethlon Medical (AEMD) Note: An Emerging Strategy to Treat Metastatic Breast Cancer
SAN DIEGO, Jan. 15, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) In 2012, researchers published the discovery that small
Read more →AEMDAethlon Medical to Present Today At Biotech Showcase 2013
SAN DIEGO, Jan. 8, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), announced that Chief Executive Officer Jim Joyce will give a corporate presentation today at Biotech Showcase 2013. The presentation is scheduled to start at 4:45 p.m. Pacific Standard Time and can be ac
Read more →AEMDAethlon Medical Discloses Submission of Hepatitis C Virus (HCV) IDE to FDA
SAN DIEGO, Jan. 3, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that it has submitted an Investigational De
Read more →AEMDAethlon Medical Announces Expansion of Compassionate-Use Program To Treat Hepatitis C Virus (HCV)
SAN DIEGO, Dec. 12, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that a compassionate-use clinical program
Read more →AEMDAethlon Medical (AEMD) Note: A Medical Device Strategy to Address Metastatic Melanoma
SAN DIEGO, Dec. 7, 2012 /PRNewswire/ --Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. At Aethlon Medical, our focus is to create revolutionary medical devices that save lives. In the treatment of Hepatitis C (H
Read more →AEMDAethlon Medical Announces Initiation of Compassionate-Use Program to Treat Hepatitis C Virus (HCV)
SAN DIEGO, Dec. 3, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the initiation of a compassionate-use clini
Read more →AEMDAethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the European Patent Office (EPO) has p
Read more →AEMDAethlon Medical Announces Issuance of Cancer Therapy Patent
SAN DIEGO, Oct. 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that U.S. Patent number 8,288,172 was issu
Read more →AEMDAethlon Medical to Present at the RedChip 15th Annual Small-Cap Conference on October 11th
SAN DIEGO, Oct. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), announced that Chairman and CEO Jim Joyce will present at the RedChip 15th Annual Fall Small-Cap Conference this Thursday, October 11, 2012 at the Palace Hotel in San Francisco. A live webcast of the pre
Read more →AEMDAethlon Medical Releases EXOSOMES & MICROVESICLES 2012 Presentation
SAN DIEGO, Oct. 3, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the slide-deck underlying a presentation given yesterday by its Chairman and CEO, Jim Joyce at the EXOSOMES & MICROVESICLES 2012 conference in Orlando, Florida. The presentation was entitl
Read more →AEMDAethlon Medical Releases Hepatitis C Virus (HCV) Treatment Protocol and Inclusion/Exclusion Criteria Underlying Compassionate-Use Commercialization Program
SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today released the treatment protocol underlying a program
Read more →AEMDAethlon Medical Announces the Appointment of Dr. Stephen Z. Fadem to its Extracorporeal Science Advisory Board
SAN DIEGO, Sept. 26, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), announced today that Dr. Stephen Z. Fadem has agreed to join the company's Extracorporeal Science Advisory Board. Dr. Fadem is active as a practicing Houston nephrologist, teacher, lecturer and researc
Read more →AEMDAethlon Medical To Present at the Exosomes and Microvesicles 2012 Conference
SAN DIEGO, Sept. 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), disclosed today that its Chairman and CEO, Jim Joyce will present at the Exosomes and Microvesicles 2012 conference, which is being hosted by The American Society for Exosomes and Microvesicles. The ev
Read more →AEMDAethlon Medical Discloses MD Anderson Cancer Center Presentation
SAN DIEGO, Sept. 11, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), disclosed this afternoon that its Chairman and CEO, Jim Joyce, and Chief Science Officer, Dr. Richard Tullis, gave a presentation yesterday at the MD Anderson Cancer Center in Houston, Texas. The prese
Read more →AEMDThisweekinMedIT.tv features the Aethlon Medical Hemopurifier®
SAN DIEGO, Sept. 10, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), disclosed that ThisweekinMedIT.tv (TWIMIT) features an interview with Chairman and CEO, Jim Joyce regarding the Aethlon ADAPT™ system and Hemopurifier®. The interview can be accessed on the company's w
Read more →AEMDAethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
SAN DIEGO, Aug. 23, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Wall Street Transcript has conduc
Read more →AEMDAethlon Medical Announces Expanded Access to Hemopurifier® Therapy For Individuals Infected with Hepatitis C Virus (HCV)
SAN DIEGO, Aug. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has agreed to establish a treatment
Read more →AEMDAethlon Medical Reports Undetectable Hepatitis C Virus (HCV) Seven Days After Initiation of Hemopurifier® Therapy in Genotype-1 Patients
SAN DIEGO, July 31, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the two most recent hepatitis c (HCV)
Read more →AEMDAethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
SAN DIEGO, July 27, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the appointment of Thomas V. Wornham and P
Read more →AEMDAethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
SAN DIEGO, June 27, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) On June 12th, I issued a detailed note referencing a la
Read more →AEMDAethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
SAN DIEGO, June 19, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the U.S. Patent and Trademark Office
Read more →AEMDAethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
SAN DIEGO, June 12, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Last week, Medical News Today reported on a cancer rese
Read more →AEMDAethlon Medical to Present at Today
SAN DIEGO, May 15, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), announced that Chairman and CEO James A. Joyce will present at today's Security Research Associates (SRA) 8th Annual Growth Stock Conference. The Conference will be held at the Le Meriden Hotel in San Fr
Read more →AEMDAethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
SAN DIEGO, May 8, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the presence of Hepatitis C virus (HCV)
Read more →AEMDAethlon Medical Note: Fiscal Year Revenue Guidance
Aethlon Medical Note: Fiscal Year Revenue Guidance SAN DIEGO - May 3, 2012 - Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. On May 19th of last year, we introduced and began marketing the Aethlon ADAPT system,
Read more →AEMDAethlon Medical Note: Marc Robins Joins the Aethlon Team
SAN DIEGO, April 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Aethlon Medical was originally formed to advance a med
Read more →AEMDAethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
SAN DIEGO, April 24, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) The gold standard for determining drug therapy benefit
Read more →AEMDAethlon Medical to Present Hepatitis C (HCV) Treatment Technology at the 32nd Annual Dialysis Conference
SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that a presentation of the Aethlon Hemopuri
Read more →AEMDAethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier® Treatment Protocol
SAN DIEGO, Feb. 1, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the administration of Hemopurifier® the
Read more →AEMDAethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
SAN DIEGO, Jan. 23, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has established an Extracorporeal
Read more →AEMDAethlon Medical Establishes Sepsis & Inflammation Scientific Advisory Board
SAN DIEGO, Jan. 12, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has established a Sepsis & Inflamm
Read more →AEMDAethlon Medical Discloses Availability of the Biotech Showcase™ 2012 Presentation
SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced that an audio rebroadcast of the presentation by its Chairman and CEO, James A. Joyce, at the
Read more →AEMDAethlon Medical Announces Biotech Showcase™ 2012 Presentation
SAN DIEGO, Jan. 4, 2012 /PRNewswire/-- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its Chairman and CEO James A. Joyce will be the lead-off presenter at the Biotech Sh
Read more →AEMDAethlon Medical Announces HIV-AIDS Research Discovery
SAN DIEGO, Dec. 13, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture parti
Read more →AEMDAethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
SAN DIEGO, Dec. 6, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifie
Read more →AEMDAethlon Medical Releases Shareholder Letter
SAN DIEGO, Nov. 16, 2011 /PRNewswire/ -- Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) To our Shareholders: Earli
Read more →AEMDAethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
SAN DIEGO, Oct. 25, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present a company overview, discuss recent developm
Read more →AEMDAethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will begin accepting orders for its Enzyme Linked Lectin Specific Assay (ELLSA™)
Read more →AEMDAethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
SAN DIEGO, Oct. 5, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® and HER2osome™ cancer therapy will be the subject of a pre
Read more →AEMDAethlon Medical Receives Government Contract Award from DARPA
SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has been awarded a $6.8 million contract from the Defense Advanced Research Proj
Read more →AEMD: Aethlon Medical Receives Government Contract Award from DARPA Contract Program Will Support The Development of an Aethlon ADAPT Sepsis Prevention Device San Diego
For Immediate Release: Aethlon Medical Receives Government Contract Award from DARPA Contract Program Will Support The Development of an Aethlon ADAPT Sepsis Prevention Device San Diego, October 3, 2011 - Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeut
Read more →AEMD"A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
SAN DIEGO, Sept. 27, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has released a white paper entitled: "A Medical Device Strategy To Inhibit HER
Read more →AEMDAethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
SAN DIEGO, Sept. 21, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today the introduction of HER2osome™, a novel medical device strategy to inhibit the progres
Read more →AEMDAethlon Medical Announces Sarcoma, Lung Cancer, Prostate Cancer, Metastatic Melanoma, and Head and Neck Cancer Studies
SAN DIEGO, Aug. 24, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has entered into an agreement with the Sarcoma Oncology Center to study the ex v
Read more →AEMDAethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
SAN DIEGO, June 7, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will provide a company overview, discuss recent developme
Read more →AEMDAethlon Medical President Rodney S. Kenley to Present at the 20th International Vicenza Course on Hemodialysis and CKD
SAN DIEGO, June 2, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD) today announced that Company President Rodney S. Kenley will discuss the role of the Aethlon Hemopurifier® in the treatment of hepatitis C virus (HCV) in an upcoming presentation at the 20th International
Read more →AEMDAethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
SAN DIEGO, May 23, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present the Aethlon ADAPT™ system in a
Read more →AEMDAethlon Medical Introduces the Aethlon ADAPT™ System
SAN DIEGO, May 19, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD) announces the introduction of the Aethlon ADAPT™ system, an adaptive dialysis-like affinity platform technology that provides a novel and potentially expedited commercialization pathway for monoclonal ant
Read more →AEMDAethlon Medical Discloses FDA Meeting Request and Proposed Expansion of U.S. Treatment Indications to Include Hepatitis C Virus (HCV)
SAN DIEGO, May 9, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD) announces that it has submitted a request to the U.S. Food and Drug Administration (FDA) for a face-to-face meeting to discuss re-initiation of an Investigational Device Exemption (IDE) study of the Aethlo
Read more →AEMDABC News Reports on Aethlon Medical
SAN DIEGO, April 20, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it is the subject of an ABC news story that can be accessed online at: http://www.
Read more →AEMDAethlon Medical Clarifies News Report
SAN DIEGO, April 20, 2011 /PRNewswire/ -- Earlier today, Aethlon Medical, Inc. (OTCBB: AEMD) disclosed that it was the subject of an ABC affiliate station news story that included discussion of the company's proposed strategy to reduce the occurrence of sepsis in wounded military
Read more →AEMDAethlon Medical Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV
SAN DIEGO, April 15, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that InvestorIdeas.com has released an interview with Aethlon CEO Jim Joyce regarding
Read more →AEMDAethlon Medical Announces Multi-Target Exosome Assay Validation
SAN DIEGO, April 12, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying
Read more →AEMDAethlon Medical Discloses Part II of Emerging Opportunities in Biodefense Interview
SAN DIEGO, April 1, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that InvestorIdeas.com has released the second installment of an interview regarding eme
Read more →AEMDAethlon Medical Discloses Emerging Opportunities in Biodefense Interview
SAN DIEGO, March 25, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that InvestorIdeas.com has released an interview regarding emerging oppor
Read more →AEMDAethlon Medical Receives FDA Approval to Export its Hemopurifier® to India
SAN DIEGO, March 8, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Aethlon's req
Read more →AEMDJim Joyce Chairman, CEO Forward Looking Statements MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR HEMOPURIFIER A
Forward Looking Statements MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR HEMOPURIFIER AND OTHER PRODUCT OFFERINGS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACC
Read more →AEMDAethlon Medical to Present at the Wall Street Analyst Forum 22nd Annual Investor Conference
SAN DIEGO, Feb. 15, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will present at the Wall Street Analyst Forum 22nd Annual Investor
Read more →AEMDAethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India
SAN DIEGO, Feb. 10, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its President, Rod Kenley, was invited to present at the 4th Congress
Read more →AEMDThe Evolution of Therapeutic Filtration to Improve Hepatitis-C Virus (HCV) Treatment Outcomes Therapeutic filtration of HCV from the entire circulatory system with a medical device has been clinically demonstrated to imp
The Evolution of Therapeutic Filtration to Improve Hepatitis-C Virus (HCV) Treatment Outcomes Therapeutic filtration of HCV from the entire circulatory system with a medical device has been clinically demonstrated to improve treatment outcomes when administered at the outset of
Read more →AEMDU.S. Department of Health and Human Services BARDA Industry Day Presentation Washington, DC
U.S. Department of Health and Human Services BARDA Industry Day Presentation Forward Looking Statements MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR HEMOPURIFIER AND
Read more →AEMDAethlon Medical to Host Investor Event on January 20, 2011
SAN DIEGO, Jan. 5, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will host an investor event at 5:30 pm PST on January 20, 2011 at t
Read more →AEMDAethlon Medical Demonstrates Ability to Capture Colorectal and Lymphoma Cancer Exosomes
SAN DIEGO, Dec. 20, 2010 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes
Read more →AEMDAethlon Medical Announces Washington, DC Shareholder Presentation
SAN DIEGO, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will host a presentation for shareholders and other inte
Read more →AEMDAethlon Medical Announces Presentation at U.S. Department of Health and Human Services BARDA Industry Day
SAN DIEGO, Dec. 14, 2010 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has accepted an invitation to present at the U.S. Department of He
Read more →AEMDJIM JOYCE CHAIRMAN
MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER AND OTHER PRODUCT OFFERINGS, RE
Read more →AEMDAethlon Medical to Present at 3rd Annual LD MICRO Conference on December 9th
SAN DIEGO, Nov. 23, 2010 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will present at the LD MICRO Conference on Thursday, December 9th,
Read more →AEMD'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc.
SAN DIEGO, Nov. 18, 2010 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has released a report entitled: "A Platform to Address Bioterroris
Read more →AEMDAethlon Medical to Present at the Singular Research Fifth Annual
SAN DIEGO, Nov. 3, 2010 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it will present tomorrow at the at the Singular Research Fifth Annual
Read more →AEMDAethlon Medical Names Rod Kenley President
SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has named Rod Kenley to be President of Aethlon Medical. Aethl
Read more →AEMDAethlon Medical Names Rod Kenley President San Diego, CA.
Aethlon Medical Names Rod Kenley President San Diego, CA. - October 28, 2010 - Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has named Rod Kenley to be President of A
Read more →AEMDAethlon Medical Announces the Appointment of Miriam Provost as Its U.S. Regulatory Advisor
SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has retained Miriam C. Provost, Ph.D. of the Biologics Consult
Read more →AEMDAethlon Medical Initiates Patient Enrollment of Hepatitis-C Virus (HCV) Clinical Studies
SAN DIEGO, Oct. 21 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today it has established primary clinical endpoints and clarified efficacy a
Read more →AEMDAethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that Rod Kenley has been appointed to the Aethlon Medical board of dir
Read more →AEMDAethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
SAN DIEGO, Sept. 30 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has engaged Fabiani & Company to assist in the establishment of federal
Read more →AEMDAethlon Medical Appoints Jim Frakes as Chief Financial Officer
SAN DIEGO, Sept. 28 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has appointed Jim Frakes, currently serving as Senior Vice Pr
Read more →AEMDAethlon Medical Reestablishes Biodefense Programs
SAN DIEGO, Sept. 21 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier® within U
Read more →AEMDAethlon Medical Announces Data Against Metastatic Melanoma
SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemo
Read more →AEMDAethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
SAN DIEGO, Aug. 30 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its Chairman and Chief Executive Officer, Jim Joyce, will present at the Ro
Read more →AEMDAethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
SAN DIEGO, Aug. 26 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The M
Read more →AEMDAethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
SAN DIEGO, Aug. 18 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, today announced that it has entered into an agreement with GVK Biosciences (GVK BIO) t
Read more →AEMDDESCRIPTION OF COMMON STOCK The authorized capital stock of Aethlon Medical, Inc. (the "Company") consists of 250,000,000 shares of common stock, par value $0.001 per share. Our common stockholders are entitled to one vo
DESCRIPTION OF COMMON STOCK The authorized capital stock of Aethlon Medical, Inc. (the "Company") consists of 250,000,000 shares of common stock, par value $0.001 per share. Our common stockholders are entitled to one vote per share on all matters to be voted upon by those stock
Read more →AEMDPOLICY STATEMENT ON INSIDE INFORMATION AND SECURITIES TRADING OF AETHLON MEDICAL, INC. As adopted by the Board of Directors on
STATEMENT ON INSIDE INFORMATION AND SECURITIES TRADING OF AETHLON MEDICAL, adopted by the Board of Directors on March 1, 2010 result of your position as a director, officer, or employee of Aethlon Medical, Inc. (the "Company," "we," or "us"), you are likely to learn or have ac
Read more →AEMDFINAL ----- AETHLON MEDICAL AND FUSION CAPITAL ENTER INTO PRIVATE PLACEMENT AGREEMENT AND MUTUALLY TERMINATE MARCH 2007
aethlon_8kex99-1.txt PRESS RELEASE DATED MAY 1, 2008 AETHLON MEDICAL AND FUSION CAPITAL ENTER INTO PRIVATE PLACEMENT AGREEMENT AND MUTUALLY TERMINATE MARCH 2007 COMMON STOCK PURCHASE AGREEMENT SAN DIEGO, CA, May 1, 2008, -- Aethlon Medical, Inc. (OTCBB: AEMD), today announc
Read more →AEMDaethlon LOGO HERE] FOR IMMEDIATE RELEASE: Contact: Jeff Richardson Senior Director, Communications 858.459.7800 x302 jrichardson@aethlonmedical.com Dylan Hundley Senior Director, Investor Relations 646-435-4069 dhundley@
aethlon_8kex99-1.txt PRESS RELEASE DATED MARCH 22, 2007 FOR IMMEDIATE RELEASE: Contact: Senior Director, Communications jrichardson@aethlonmedical.com Senior Director, Investor Relations dhundley@aethlonmedical.com AETHLON MEDICAL EXECUTES $8.4 MILLION COMMON STOCK PURCHA
Read more →AEMDTHE TREATMENT OF H5N1 AVIAN INFLUENZA REPORT: RELEASED BY AETHLON MEDICAL Wednesday March 15, 4:05 pm ET SAN DIEGO--(BUSINESS WIRE)
aethlon_8kex99-1.txt THE TREATMENT OF H5N1 AVIAN INFLUENZA REPORT: RELEASED BY AETHLON MEDICAL Wednesday March 15, 4:05 pm ET SAN DIEGO--(BUSINESS WIRE)--March 15, 2006--Aethlon Medical, Inc. (OTCBB:AEMD -News), a pioneer in developing therapeutic devices for infectious disea
Read more →AEMDaethlon Medical, Inc. FOR IMMEDIATE RELEASE: Contact: Jeff Richardson Senior Director, Communications 858.459.7800 x302 jrichardson@aethlonmedical.com James A. Joyce Chairman, CEO 858.459.7800 x301 jj@aethlonmedical.com
aethlon Medical, Inc. FOR IMMEDIATE RELEASE: Contact: Senior Director, Communications jrichardson@aethlonmedical.com jj@aethlonmedical.com AETHLON MEDICAL EXPANDS DEVICE PIPELINE TO INCLUDE THE TREATMENT OF CANCER San Diego, CA, February 23, 2006 - Aethlon Medical, Inc., (
Read more →AEMDAETHLON MEDICAL, INC. FOR IMMEDIATE RELEASE: Contact: Anne Hoversten Aethlon Medical, Inc. Investor Relations 858.459.7800 x300 anne@aethlonmedical.com AETHLON MEDICAL APPOINTS JAMES W. DORST AS CHIEF FINANCIAL OFFICER S
aethlon_8kex99-1.txt AETHLON MEDICAL, INC. FOR IMMEDIATE RELEASE: Contact: Aethlon Medical, Inc. anne@aethlonmedical.com AETHLON MEDICAL APPOINTS JAMES W. DORST AS CHIEF FINANCIAL OFFICER San Diego, CA, August 2, 2005 - Aethlon Medical, Inc. (OTCBB:AEMD) announced today t
Read more →Competitive Position
How AEMD ranks across every disease it competes inCompetitive Position is a premium feature
See how AEMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial